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SUMMARY
Of the many cells in the body, the hematopoietic cells are among those with
the highest rate of self-renewal and turnover. The production and destruction
of these cells are tightly controlled by a number of hematopoietic growth
factors, in particular by members of the family of helical cytokines. Studying
the thrombopoietin receptor, I focused on two aspects of cytokine receptor
signaling: attenuation of signaling by receptor isoforms and the biological
function of cytokine receptor target genes.
Cytokine receptor signaling has profound effects on cell survival, proliferation
and differentiation. It is therefore not surprising that components of the
signaling cascade are tightly regulated at the level of expression. An important
mechanism for controlling gene expression is alternative splicing. Alternate
isoforms have been identified for many cytokine receptors and a regulatory
function and/or altered expression in disease have been described for some
of these isoforms
The cytokine thrombopoietin (TPO) and its cognate receptor c-mpl are the
primary regulators of platelet production and also play an important role in
hematopoietic stem cell biology. Several isoforms of unknown function exist
for both mouse and human mpl and it is possible that they play an important
role in modulating mpl signaling. In my thesis work, I have analyzed the
function of a truncated receptor isoform (mpl-tr) which is the only alternate mpl
isoform conserved between mouse and humans. Although mpl-tr lacks a
transmembrane domain, classifying it as a ‘secreted’ or ‘soluble receptor’, it is
retained intracellularly. My results provide evidence that mpl-tr acts as a
dominant-negative variant of mpl for both proliferation and survival. I also
demonstrate that mpl-tr mediates protein degradation of the full-length
receptor by a cathepsin-like cysteine protease activity. Due to a shift of the
reading frame at a splice acceptor site, the C-terminus of mpl-tr consists of a
peptide of unique sequence, 30 amino acids in length. I show that this peptide
sequence is essential for the inhibition of TPO-dependent proliferation and for
mpl protein degradation mediated by mpl-tr. Together, these data suggest a
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new paradigm for the regulation of cytokine receptor expression and function
through a proteolytic process directed by a truncated isoform of the same
receptor.
To test for the in vivo function of alternative mpl isoforms, a c-mpl cDNA was
expressed as a transgene in mpl knockout mice. These mice express mpl full-
length as the only mpl isoform and develop severe thrombocytosis with
platelet numbers, elevated about five times higher than normal. The
reintroduction of the endogenous mpl allele restores normal platelet counts
and I attribute this to the in vivo effect of dominant-negative mpl isoforms. A
mpl knock-in allele, which does not express mpl-tr but still expresses the
second known alternate variant of murine mpl, mpl-II, normalizes platelet
numbers, similar to the endogenous mpl allele. This result demonstrates that
the absence of mpl-tr is not sufficient to cause thrombocytosis. I propose that
mpl-II is an additional dominant-negative mpl isoform and attenuates the
expansion of the megakarocytic lineage in vivo. In summary, these results
impressively demonstrate the importance of alternate cytokine receptor
isoforms in vivo and emphasize the need to study the function of the many
uncharacterized cytokine receptor isoforms.
In a second project, I studied the role of mpl signaling in regulating the
expression of a gene with a potential role in cell differentiation and
proliferation. The diversification of cell types is controlled through the use of
both lineage-restricted and more widely expressed transcriptional regulators
and the combinatorial actions of these regulators specify gene expression.
The differentiation of megakaryocyte precursors is dependent on the proper
function of the GATA-1 transcription factor. Mice lacking GATA-1 selectively in
megakaryocytes have dramatically fewer platelets but more megakaryocytes,
altered platelet size and shape and prolonged bleeding times. Further, GATA-
1-null megakaryocytes hyperproliferate in vitro, suggesting that GATA-1 is
both a differentiation factor and negative regulator of megakaryocyte cell
proliferation. However, GATA-1 regulated genes which are responsible for this
growth inhibition are presently unknown. In this thesis work, I describe a novel
gene, GASIP (GATA-1 regulated SIAH Interacting Protein), which is
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dramatically downregulated in mpl-transfected hematopoietic cell lines,
identifying mpl as a negative regulator of GASIP expression. The presence of
juxtaposed GATA and Ets-binding cis-elements in the GASIP promoter are
typical for a megakaryocytic gene. I found that GASIP expression in platelets
is indeed robust and correlates with mRNA levels of GATA-1, but not GATA-2
or –3, identifying GATA-1 as a positive regulator of GASIP expression. The
finding that mpl and GATA have opposite effects on both proliferation and on
GASIP expression, make GASIP a candidate GATA-1 target gene involved in
growth inhibition. To investigate the potential role of GASIP in growth
regulation, I screened for potential protein binding partners. Interestingly, I
identified the p53-inducible tumor suppressor seven in absentia homologe
(SIAH) as a GASIP interacting protein. I speculate that GASIP may contribute
to the anti-proliferative effect mediated by SIAH.
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GENERAL INTRODUCTION
Hematopoiesis
Vertebrate blood consists of multiple cell types that perform varied and
specific functions. Though distinct, all blood cell types are derived from a
common, pluripotent precursor or hematopoietic stem cell (HSC) 3. The onset
of vertebrate hematopoietic development, generally termed primitive
hematopoiesis, occurs during embryogenesis when the extraembryonic yolk
sac (or an equivalent site) gives rise to blood precursors, which are primarily
erythroid in nature 4. A second round of de novo hematopoietic development,
termed definitive hematopoiesis, occurs in the mesodermal
aorta/gonad/mesonephros (AGM) region of the embryo proper and gives rise
to cells that will seed subsequent hematopoietic sites, such as the fetal liver
and the bone marrow in mammals, as well as to all blood cell types found in
the mature organism 5. The myeloid lineage gives rise to multiple cell types
including erythrocytes, megakaryocytes (from which platelets are derived),
and macrophages, which primarily function as professional phagocytes in the
context of both development and innate immunity 6. The lymphoid lineage
primarily mediates adaptive immunity through the production of B and T cells
and natural killer cells 7. Proliferation and differentiation of the HSC and
lineage restricted precursor cells are largely regulated by the interaction of
these cells with soluble signaling molecules, especially cytokines.
Cytokines and their receptors
Many aspects of cell behavior, such as growth, motility, differentiation, and
apoptosis, are regulated by signals which cells receive from their
environment. Upon ligand binding, receptors become activated and thereby
initiate a cascade of intracellular events. The initial ligand/receptor interaction
seems to be the most specific step in this cascade. The specificity of
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ligand/receptor interaction has been well studied in the field of cytokines and
their receptors 8.
The helical cytokines constitute a family of secreted proteins of a molecular
weight of usually 20 to 30 kDa. The amino acid sequences of different
cytokines display no apparent homology but share a common three-
dimensional structure of an anti-parallel “four-helix bundle” with a
characteristic up-up-down-down topology 9. This topology demands that the
three loops connecting the four helices are long-short-long (Fig.1).
All these cytokines transmit their signal into the cell by multi-subunit receptor
complexes. Subfamilies of cytokines have been classified based shared
signal-transducing receptor subunits. One such receptor-subunit is gp130,
which is shared by the Interleukin-6 (IL-6) type cytokines as part of the signal-
transducing complex. Similarly, the b-subunit of the IL-3 receptor is shared by
IL-3, IL-5, and the granulocyte macrophage colony stimulating factor (GM-
CSF), while the IL-2g receptor is the common subunit for IL-2, IL-4, IL-7 and
IL-15 10.
The growth hormone (GH) receptor complex was the first four-helical cytokine
receptor to be crystallized together with its ligand 11 and has therefore
become pivotal for the understanding of four-helical cytokine receptor
complexes. One GH molecule binds to two receptor molecules via two contact
epitopes designated as site I and II. Remarkably, the two receptors use
identical amino acid residues to bind to the two different epitopes of the
cytokine 11,12. One conclusion derived from these studies is that cytokines are
recognized by their cognate receptors at sites equivalent to site I and II of GH
8,11. Biochemical studies demonstrated the existence of an additional site III
on IL-6 and a requirement for two distinct binding epitopes on the receptor for
activation 13-16.
The cytokine receptor superfamily is defined by the presence of the cytokine-
receptor homology region (CRH) consisting of two immunoglobulin domains,
whereby the loops connecting the b-sheets establish the specific contact to
the ligand 17. Within the cytokine receptor superfamily, two subclasses can be
distinguished. The CRH domain of class I receptors contains two conserved
disulfide bridges and a typical sequence motif tryptophan-serine-X-
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tryptophan-serine (WSXWS) in the membrane proximal immunoglobin
domain. In contrast, the CRH domain of class II receptors lacks the WSXWS
motif and the first conserved disulfide bridge. Instead, a distinct disulfide
bridge is formed at the C-terminus of the membrane proximal immunoglobulin
domain 8. In addition to CRH domains, the extracellular domain of cytokine
receptors can contain several membrane proximal fibronectin type III (FN III)
domains. The intracellular portion of cytokine receptors is very diverse in
length and shows little homology. No enzymatic activity has been identified for
the intracellular domain. However, many members of the cytokine receptor
family are associated with kinases of the janus activated kinase (JAK) family
through two membrane-proximal proline rich sequence motifs called box 1
and box 2. In contrast, TNF receptor (TNFR)-1 and –2 show neither intrinsic
enzymatic activity nor are they directly associated with enzymes. Although
TNFR-1 and –2 are activated by the same ligand, they initiate different
signaling cascades due to their different intracellular modules. TNFR-1
contains an intracellular death domain, which interacts with proteins named
TRADD leading to the activation of a number of proteases of the caspase
family. The TNFR-2 does not contain a death domain but interacts with the
FADD protein 18.
Most cytokines cause receptor dimerization or oligomerization upon binding.
In these cases, dimerization or oligomerization is required and sufficient for
the onset of the signal transduction. Interestingly, it has been shown that
dimerization is required but not sufficient for some of the homodimeric
Fig.1. Computer representation of
porcine GH crystal structure. The
four antiparallel -helical bundles are
represented as cylindrical rods and
labeled with Roman numerals I–IV.
The amino and carboxyl termini are
indicated with an N and C,
respectively. The numbers indicate
amino acid positions at the N and C
termini of each independent -helix.
(Adapted from S. S. Abdel-Meguid
et al. 2)
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receptors to signal and that these receptors exist as preformed dimers on the
cell surface. Crystallographic and biochemical studies have demonstrated that
the erythropoietin receptor (EpoR) as well as TNFR-1 can form dimers in the
absence of their ligands 19,20. It has been demonstrated that distinct dimeric
configurations exist for EpoR dependent on whether it is liganded or
unliganded, or bound to agonistic or antagonistic peptides 19,21,22. The
presence of a ligand and its agonist or antagonist activity resulted in different
distances and orientations of the receptor parts close to the membrane 19.
Beyond the evidence that preformed dimers exist, the structure of the
unliganded receptors revealed that the dimerization occurs via epitopes that
are also involved in ligand binding 19. Therefore, ligand binding to EpoR can
be regarded as a competition event in which the ligand binds the dimerized
receptor and replaces the direct physical interaction between the two receptor
chains. As a consequence, the intracellular domains of the two receptor
molecules change their relative orientation to one another.
JAK/ STAT signaling
Janus kinases (JAK)s include four family members (JAK1-3 and TYK2) with
molecular masses of 120-130 kDA. Whereas, JAK1, JAK2, and TYK 2 are
expressed ubiquitously, expression of JAK3 is confined to hematopoietic and
lymphoid cells 23,24. These nonreceptor tyrosine kinases associate with
members of the cytokine receptor family through conserved membrane
proximal motifs, termed box 1 and 2, in the receptor 25. JAKs lack true src
homology 2 or 3 domains (SH2 and SH3), and the precise nature of the
physical association between receptor and kinase is unknown. Box 1, defined
by two appropriately spaced prolines (PXXP), is located within the first 30
cytoplasmic residues of most cytokine receptors and is similar to the core
binding sequence of SH3 proteins. Box 2 is defined by the frequent
occurrence of acidic and serine residues and is located between cytoplasmic
amino acids 45 and 69 in mpl. The exact boundaries of box 2 are unknown.
However, mutations or deletions of either box 1 or 2 completely disrupt all
measurable JAK activity. Characteristic of the structure of JAKs is the
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presence of two JAK homology (JH) domains, of which the C-terminal (JH1)
domain has tyrosine activity 25. Upon receptor oligomerization, JAKs are
activated, presumbly by trans-‘auto’ phosphorylation on tyrosines.
Subsequently, JAKs phosphorylate signal transducer and activators of
transcription (STAT) proteins, which form homodimeric or heterodimeric
complexes via their SH2 domains. These complexes translocate to the
nucleus, where they bind to specific enhancer sequences and influence gene
transcription 26. Thus far, six mammalian STAT proteins (plus several
isoforms) have been identified 27. Two homologS exist of STAT 5 (STAT5A
and STAT5B) that are encoded by different genes. Expression of STAT
proteins is ubiquitous, except for STAT4, which is expressed in several
tissues including spleen, heart, brain, peripheral blood and testis 28. While
STAT1, STAT3 and STAT5 are activated by multiple receptors, activation of
STAT4 and STAT6 is restricted to the receptors for IL-12 and IL-4/IL-13,
respectively 29-31. Phosphorylated tyrosines and flanking amino acid residues
in the activated cytokine receptor determine this specificity by providing
docking sites for the SH2 domains of STATs 32,33. The tyrosine
phosphorylation of the receptor proteins is also likely to be directly mediated
by JAKs.
Negative regulatory mechanisms of cytokine signaling
Of equal importance to the positive mechanisms initiated by cytokine signals
are the negative regulatory mechanisms that serve to dampen or terminate
cytokine signals 34,35. Three classes of negative regulatory proteins have been
discovered: phosphatases, PIAS and SOCS proteins – their importance being
vividly demonstrated by mice lacking these inhibitors. Each of these protein
families appears to act at a distinct point and at a particular time in the
cytokine signaling cascade (Fig. 2). Additionally, alternatively spliced cytokine
receptor variants have emerged as important negative regulators of cytokine
signaling 36-38.
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The SOCS family of cytokine signal suppressors
One recently identified protein family of inhibitors of cytokine signaling is the
SOCS (suppressor of cytokine signaling) family. The first member of this
family, CIS (cytokine-inducible SH2-domain-containing protein), was identified
as an immediate-early gene, induced by IL-3, that inhibited signaling and
proliferation  35. Using different strategies, three other family members, termed
SOCS1, JAB (JAK binding protein) and SSI1 (STAT-induced STAT inhibitor
1), were subsequently separately cloned 39,40. The SOCS family now includes
eight members, CIS and SOCS1-SOCS7 41.
The mRNA and protein expression for SOCS members is rapidly induced by a
variety of stimuli, including cytokines and growth factors. Importantly, SOCS
expression is reduced in mice lacking various STAT genes but, in addition,
there are examples of SOCS induction in response to stimuli that do not
activate STATs, such as lipopolysaccharide or IL-1. Functioning as a classic
negative feedback loop, SOCS proteins are structurally conserved but inhibit
signaling by different mechanisms. SOCS-box-containing proteins can be
divided into five subfamilies of proteins with SH2 domains, WD-40 repeats,
ankyrin repeats, SPRY domains or GTPase domains 41. The function of the
SOCS-box has not been established but several lines of evidence point to a
role in ubiquitin-mediated protein degradation, potentially through the binding
of the elongin BC complex 42. The elongins bind to E3 ligase complex of CUL
2 and Skp1 and this may regulate protein turnover. The function of SOCS
proteins other than CIS and SOCS1-SOCS3 are currently not well
understood.
CIS
CIS, the first member of the SOCS family to be identified, is induced by Epo,
IL-3, GH, IL-2 and by Prl, and it competes with STATs for the receptor
phosphotyrosine residues that serve as a docking site. CIS transgenic mice
have low birth weight, stunted growth and defective mammary gland
development, possibly due to a complete block of Prl signaling, a phenotype
similar to that observed with Stat5-/- mice 43. However, the lack of a clear
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phenotype in the CIS-/- mice suggests that, unlike other SOCS family
members (see below), it may be redundant 44.
SOCS1
SOCS1 mRNA is induced by many cytokines, including IL-6, IL-2, IL-4, LIF,
IFN-a/b, IFN-g, GH and G-CSF. SOCS1 inhibits JAK1, JAK2 and TYK2 but
affects JAK3 kinase activity minimally. Mutational analysis of SOCS1 and
SOCS3 has established that both the SH2 domain and an amino-terminal
kinase-inhibitory region (KIR), but not the SOCS-box, are essential for
blocking JAK activity and cytokine signaling. Interessingly, the KIR is not
found in other SOCS 45-47 although SOCS4 and SOCS5 have amino-terminal
regions with sequences similar to KIRs. SOCS1-/- mice, though born healthy,
rapidly succumbed to a complex, multiorgan disease characterized by
leukocytic infiltration and necrosis with severe B cell lymphopenia. SOCS1-/-
mice have activated STAT1 in the liver, have elevated expression of IFN-g-
inducible genes, are hypersensitive to IFN-g and have elevated circulating
levels of this cytokine 48,49. Accordingly, mice lacking both SOCS1 and IFN-g
are healthy, as are doubly deficient SOCS1-/- Rag2-/- mice.
SOCS2
SOCS2-/- mice are born at the expected Mendelian ratio, survive weaning
and are healthy and fertile as adults 50. Male SOCS2-/- mice grow more
rapidly than their wild-type counterparts; SOCS2-/- females are also heavier,
but less dramatically so. With the notable exception of the brain, most organs
in SOCS2-/- animals are proportionately large and the long bones are 7-15%
longer. The increased weight of SOCS2-/- animals is not due to increased fat;
rather the animals are if anything leaner than normal, a phenotype similar to
that of GH transgenic mice. The mechanism of SOCS2 action in regulating
body size is not entirely clear but an important mechanism of GH action is the
induction IGF1 (insulin-like growth factor 1). Notably, SOCS2-/- animals
exhibit elevated expression of IGF1 mRNA in a number of tissues, including
the heart, lung and spleen.
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SOCS3
Like SOCS1, SOCS3 can inhibit STAT activation in response to many
cytokines, including GH, leptin, IL-2, IL-4 and IL-10; SOCS3 is also induced in
response to most four--helical cytokines tested. SOCS3 only partially inhibits
JAK activation but its effect is enhanced in the presence of receptors,
suggesting that SOCS3 inhibits cytokine responses by binding to
phosphorylated components of the receptor complex 51,52. For gp130, an SH2-
domain-containing protein tyrosine phosphatase 2 (SHP-2)-interaction site
(YEPY757STV) is also a SOCS3 contact site; SOCS3 may compete for the
SHP2-gp130 interaction site 53,54. SOCS3-/- mice die during mid-gestation,
(between day 11.5 and day 16.5) though the basis of this embryonic lethality
is unclear. Some mice display marked erythrocytosis, consistent with the
finding that a SOCS3 transgene results in severe anemia 44. However,
reconstitution of irradiated mice with SOCS3-/- fetal liver results in normal
hematopoiesis, suggesting that the critical role of SOCS3 may be limited to
embryogenesis. Clearly, many questions remain regarding the physiological
role of SOCS3.
PIAS: negative regulators of STATs
In mammals, the PIAS (protein inhibitors of activated STATs) proteins were
first discovered as transcriptional coregulators of the JAK/STAT pathway 55.
Four members have been identified: PIAS-1, -3, -X and -Y. They share
homology amongst themselves but have no previously characterized motifs
56. PIAS proteins may not be specific for STAT interaction, as PIAS haven
been shown to interact with a number of different pathways 57; the in vivo
relevance of this family of proteins will need to be assessed by the production
of the relevant knockout mice.
Phosphatases in attenuating cytokine mediated signals
SHP-1
Given the importance of tyrosine kinases in initiating signaling, it comes as no
surprise that tyrosine phosphatases are also important inhibitors. For
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instance, SHP-1 is an important negative regulator, as illustrated by the
`motheaten mice' phenotype. The lack of SHP-1 affects almost all
hematopoietic lineages and results in the characteristic motheaten
appearance of the coat and fatal pneumonitis resulting from unchecked
neutrophil and macrophage proliferation 58. Several hematopoietic receptors,
including the IL-4R, EpoR, GHR and IL-2R have been shown to recruit SHP-
1. The mechanism by which SHP-1 inhibits signaling has not been entirely
elucidated but it presumably occurs via SH2-phosphotyrosine interaction.
SHP-1 may directly dephosphorylate and inactivate JAKs or dephosphorylate
other key tyrosines on the cytokine receptors that are involved in signaling.
Loss of SHP-1 expression has been implicated in human lymphoproliferative
disease and may be involved in malignant transformation, as reported with
HTLV-1 associated leukemia and other tumors.
SHP-2
The action of SHP-2 is more complicated. Though it has been reported to
inhibit signaling by some cytokines, it also acts as an adaptor protein,
enhancing PI-3'K and Ras activation. SHP-2 binds the receptor and recruits
Grb-2 and SOS, thus initiating Ras activation. SHP-2 does not bind all
receptors directly; it also binds docking proteins such as Gab-2 59,60.
SHIP
Two phospholipid phosphatases, SHIP (SH2-containing inositol phosphatase)
and PTEN, target PIP-3 but at different positions on the inositol ring 61.
Normally PTEN antagonizes the activation of PI3'-K and PKB/Akt by growth
factors. Many tumors and cell lines have PTEN mutations, resulting in
activation of the Akt/PKB and phosphatidylinositol PI3'-K pathway. This can
antagonize the apoptosis induced by cytokine withdrawal.
CD45 and putative STAT phosphatases
Recently, it has been shown that the absence of CD45 leads to augmented
JAK and STAT phosphorylation in hematopoietic cells. Whether the major role
of CD45 is to statically influence JAKs or whether there is a dynamic
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component of regulation is not known. Whether other receptor phosphatases
affect JAKs in nonhematopoietic cells will also need to be determined 62.
Finally, STATs are dephosphorylated over time and this presumably reflects
the activity of a STAT phosphatase. The identity of the major STAT
phosphatase and its intracellular location remains enigmatic.
Dominant-negative receptor isoforms
Most members of the family of hematopoietic growth factor receptors have
been shown to be capable of giving rise to soluble forms 63. Because most of
these soluble receptors, when expressed as recombinant proteins, act to
neutralize their cognate ligands, they are considered to function as receptor
antagonists 64-66. A different class of dominant-negative isoforms has been
described for the erythropoietin receptor (EpoR) and the common b-receptor
subunit of the granulocyte-macrophage colony-stimulating factor receptor (b-
GMR). EpoR-T is an intracytoplasmic truncated splice variant and believed to
function by forming a non-functional heterodimer with EpoR 67. Recently,
Wagner et al. have
characterized the intracytoplasmic truncated variant of b-GMR (b-GMRIT) as a
dominant-negative isoform 68. They demonstrated that b-GMRIT is trafficking
to the plasma membrane and that surface expression of the a/b-GMR
complex remains unchanged in the presence of b-GMRIT. In analogy to EpoR-
T, they proposed that the inhibitory effect of b-GMRIT was due to the formation
of non-functional complexes between a-GMR and the truncated b-GMR form.
The vast number of cytokine receptor isoforms suggests that the play an
important role in modulating cytokine receptor signaling.
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Fig. 2. Overview of Cytokine Signaling: Positive and Negative Regulation.
Cytokines bind to homodimeric or heterodimeric receptors, which bind Janus kinases
(JAKs). JAKs are activated by transphorylation and they in turn phosphorylate
cytokine receptors, allowing STATs to bind via SH2-phosphotyrosine interactions.
STATs themselves are phosphorylated, permitting STAT dimerization and
translocation to the nucleus where STATs bind DNA and regulate gene expression.
This process is regulated at multiple steps, some of which are summarized here:
tyrosine phosphatases such as SHP-1, CD45, and PTP1b may regulate
phosphorylation of receptors and JAKs. Dimerized STATs can be bound by PIAS
members, which have been found to be SUMO E3 ligases; the depicted sumoylation
of STATs, however, is a speculative, albeit reasonable, possibility. Additionally,
cytokine stimulation induces the transcription of a family of SH2 containing proteins
known as SOCS proteins. SOCS proteins inhibit signaling by multiple means: (1)
binding and inhibiting JAKs, (2) binding cytokine receptors and blocking STATs
recruitment, and (3) promoting ubiquitination and degradation of the JAK/receptor
complex. STATs are dephosphorylated in the nucleus, but the identity of the
predominant nuclear STAT phosphatase (N-PTP) remains to be determined.
Thrombopoietin and Thrombopoietin receptor c-mpl
Thrombopoietin (TPO) and its receptor c-mpl support all of the developmental
stages necessary for megakaryocytopoiesis, i.e. the generation of
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thrombocytes or platelets 69. The first evidence for the existence of a humoral
thrombopoietic growth factor came from studies of the murine
myeloproliferative leukemia virus (MPLV) 70. The viral oncogene, v-mpl, was
recognized to encode a truncated but novel member of the cytokine receptor
superfamily 71. Cellular homologs were cloned from human and mouse
tissues 72-74. The mpl ligand, TPO, was cloned soon thereafter 75. The N-
terminal portion of TPO has marked homology to erythropoietin and is
predicted to display the structure typical for helical cytokines 76. The gene
encoding mpl is located on human chromosome 1p34 and is composed of 12
exons 77 (Fig. 3). The corresponding murine gene is on chromosome 4 and
has a similar organization 78. Four distinct mRNA species exist in humans.
The predominant form encodes the full-length receptor. The Mpl-K variant is
due to a read through beyond the exon 10 splice donor site and encodes a
protein that diverges form the native Mpl sequence after the ninth cytoplasmic
amino acid and terminates within intron 10 with 66 predicted cytoplasmic
residues 73. Mpl-del, a third isoform, arises as a consequence of alternative
splicing between exons 8 and 9 and encodes a protein with an in-frame
deletion of 24 amino acids 79. The fourth mRNA species is the only one found
both in human and murine cells. It results from splicing of exon 8 directly to
exon 11, eliminating the juxtamembrane WSXWS motif and the
transmembrane domain. The resulting isoform mpl-tr lacks the cytoplasmic
domain and terminates instead in a short stretch of residues of novel
sequence due to an altered reading frame at the splice acceptor site of exon
11 72,74. Additionally, an alternative splice acceptor site in exon 4 of murine
mpl (but not human) generates an isoform with an in-frame deletion of 60
residues in the extracytoplasmic domain 80 (Fig. 3).
Both TPO 81 and mpl 82,83 knockout mice are viable but have a 90% reduction
in platelet counts. A reduction in progenitor cell numbers and a decrease in
megakaryocyte ploidy cause the thrombocythemia in these mice. However,
the megakaryocytes and platelets produced in the absence of TPO or mpl
appear to be morphologically and functionally normal, indicating that in vivo
the main role of TPO is to control their numbers, rather than their maturation.
Analysis of these gene-targeted mice provides substantial evidence to a
model where the circulating TPO level is directly regulated by platelet mass
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through binding to mpl receptors at the platelet surface. This elegant feedback
mechanism allows a tight regulation of the amount of TPO available to
stimulate megakaryopoiesis 84. In addition to its effects on megakaryopoiesis,
TPO also affects hematopoietic stem cells 85 as measured by the reduction of
repopulating capacity of bone marrow cells from mpl-deficient mice 86.
Fig. 3 Alternative mpl splice variants. The gene encoding c-mpl is composed of 12
exons 77. In humans four distinct mRNA species are known. The predominant form
encodes the full-length protein. The human Mpl K-form is due to a readthrough
beyond the exon 10 splice donor site 73. Mpl-del, a third isoform, arises as a
consequence of alternative splicing between exons 8 and 9 79. The fourth mRNA
species is the only one found both in human and murine cells. It results from splicing
of exon 8 directly to exon 11, eliminating the transmembrane domain (TM), which is
encoded by exon 10 72,74. Additionally, an alternative splice acceptor site in exon 4 of
murine mpl (but not human) generates an isoform (mpl-II) 80.
Thrombopoietin signaling
Like other class I cytokine receptors, the TPO receptor mpl makes a single
pass through the cell membrane. The extracellular domain consists of two
CRH domains, which are most similar to the CRH of EpoR. The cytoplasmic
portion of mpl is highly conserved across species and lacks any intrinsic
enzymatic function. Instead, JAK family members associate with mpl through
interaction with box 1 and box 2. The family member JAK2 is the
predominantly phosphorylated JAK after TPO activation of purified murine
megakaryoctes 87. TPO signaling leads to the activation of STAT3 and 5 .
Recently, it has been demonstrated that members of the Src family of tyrosine
kinases are also activated by mpl signaling 88.
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Many if not most of the secondary signaling pathways activated by TPO are
also activated in response to binding of other hematopoietic growth factors to
their cognate receptors, making mpl signaling a good representative of
cytokine signaling in general 89.
Specificity of cytokine signaling
In principle, each cytokine receptor could activate a unique signaling pathway,
but this does not appear to happen. One theme that has emerged from
studies of cytokine receptors and receptor tyrosine kinases is that different
receptors stimulate similar collections of intracellular signaling pathways. For
instance, 34 known or predicted type I cytokine receptors exist 90, but only
four Janus kinases 25. Given this similarity of response, an important question
has arisen about the role of cytokine receptor signaling in cell differentiation.
There are two basic models for how unique responses might be generated by
different cytokine receptors with apparently similar intracellular signaling
events. The first model postulates that there are intrinsic differences in the
intracellular signaling pathways activated by cytokine receptors. These
differences could either be quantitative (strength or duration of the signal) or
qualitative (a different combination of intracellular pathways being activated).
In this model, the outcome of a specific cytokine signaling event is unique.
The instructive model of differentiation proposes that such unique signals
bring about the induction of lineage specific genes resulting in a distinct
developmental outcome. The second model postulates that cytokine receptors
generally signal in similar ways, but cells interpret these signals based on
their distinct developmental histories. In this model, the primary reason for the
existence of so many cytokines and their cognate receptors is to allow the
temporally and spatially appropriate activation of general signaling pathways.
It suggests that cytokine receptors employ similar generic signals that permit
the expression of predetermined, tissue-specific differentiation programs.
Examples supporting both the instructive 91,92 and the permissive 93-95 model
of cytokine function exist. In several of the experiments addressing the validity
of the instructive versus the permissive model, intracellular domains of
General Introduction 21
cytokine receptors were swapped and the function of chimeric receptors was
tested. It can be argued that the outcome of the experiments was dependent
on the arbitrary choice of the novel intracellular domain in the chimeric
receptor. Therefore, expression profiling of different cytokine receptors
remains an important task in studying cytokine receptor biology. Furthermore,
our understanding of the regulatory mechanisms of cytokine receptor
signaling is far from complete. The importance of studying the regulation of
cytokine signaling is emphasized by the existence of a number of pathological
conditions with mutations in cytokine receptors or associated signaling
molecules 96.
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RESULTS I:
ALTERNATE C-MPL ISOFORMS IN SIGNAL
ATTENUATION
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A truncated isoform of c-mpl with an essential C-terminal
peptide targets the full-length receptor for degradation
Jörn Coers, Chrisitina Ranft and Radek C. Skoda*
Department of Research, Experimental Hematology, Basel University Hospitals,
Hebelstrasse 20, 4031 Basel, Switzerland.
Running title: An isoform of c-mpl targets the full-length receptor for degradation
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Abstract
Thrombopoietin and its cognate receptor c-mpl are the primary regulators of
megakaryopoiesis and platelet production. They also play an important role in
the maintenance of hematopoietic stem cells. Here, we have analyzed the
function of a truncated mpl receptor isoform (mpl-tr), which results from
alternative splicing. The mpl-tr variant is the only alternate mpl isoform
conserved between mouse and humans, suggesting a relevant function in
regulating mpl signaling. Despite the presence of a signal peptide and the lack
of a transmembrane domain, mpl-tr is retained intracellularly. Our results
provide evidence that mpl-tr exerts a dominant-negative effect on
thrombopoietin-dependent cell proliferation and survival. We demonstrate that
this inhibitory effect is due to downregulation of the full-length mpl protein. The
C terminus of mpl-tr, consisting of 30 amino acids of unique sequence, is
essential for the suppression of TPO-dependent proliferation and mpl protein
downregulation. Cathepsin inhibitor-1 (CATI-1), an inhibitor of cathepsin-like
cysteine proteases, counteracts the effect of mpl-tr on mpl protein expression,
suggesting that mpl-tr targets mpl for lysosomal degradation. Together, these
data suggest a new paradigm for the regulation of cytokine receptor
expression and function through a proteolytic process directed by a truncated
isoform of the same receptor.
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Introduction
Cytokine receptor signaling has profound effects on cell survival, proliferation
and differentiation of the receiving cell 97. It is therefore not surprising that
components of the signaling cascade are tightly regulated at several levels.
An important mechanism for controlling gene expression is alternative splicing
allowing the synthesis of structurally and functionally distinct protein isoforms
98. Many alternative splice variants of different cytokine receptors have been
described, but the function of most of the resulting protein isoforms remains
unknown.
Cytokine receptor isoforms may be classified according to the presence or
absence of a transmembrane domain. Isoforms lacking a transmembrane
domain are often termed ‘soluble cytokine receptors’ and can fulfill different
physiological functions 63,99. In general, soluble receptors may function as
agonists by stabilizing their ligands, e.g. growth hormone and tumor necrosis
factor 100,101, or contrarily act as antagonists by competing with the membrane
bound receptor for ligand binding, e.g. epidermal growth factor and interleukin
(IL)-1 102,103. Soluble receptors can arise from alternative splicing or from
proteolytic receptor shedding on the cell surface. Isoforms generated by
alternative splicing often contain additional protein sequence due to unspliced
intron sequence and/ or a shift of the reading frame. Generally, no biological
function has been attributed to these additional stretches of amino acids.
Thrombopoietin (TPO) and its receptor “cellular homolog of myeloproliferative
leukemia” (c-mpl) are the primary regulators of megakaryopoiesis 69. The
c-mpl gene is composed of 12 exons (Fig. 1A) 77. In the mouse, two distinct
alternate mRNA isoforms are known. The transmembrane variant mpl-II is
due to usage of a cryptic splice acceptor in exon 4 resulting in a in-frame
deletion of 60 amino acids 80. No function has yet been assigned to this
isoform. The second mRNA variant encodes a truncated soluble receptor,
mpl-tr, and is the only one found both in human and mouse. This variant
results from splicing of exon 8 directly to exon 11, eliminating the
juxtamembrane extracellular part and the transmembrane domain 72,74 . Due
to an altered reading frame at the splice acceptor site of exon 11, mpl-tr
protein terminates in a short stretch of novel amino acid sequence (Fig. 1).
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Mpl-tr mRNA accounts for approximately 30% of mpl mRNA in mouse spleen
74. In spite of the presence of a signal sequence and the lack of a
transmembrane domain, mpl-tr is not secreted into the cell supernatant when
ectopically expressed in cell line 74. In human, two alternate mRNA mpl
species are known in addition to mpl-tr. The mpl-K variant is due to a
readthrough beyond the exon 10 splice donor site 73. The resulting K-form of
the receptor diverges from the native sequence after the ninth cytoplasmic
amino acid and terminates within intron 10. Mpl-del, a second isoform, arises
as a consequence of alternative splicing between exons 8 and 9 and encodes
a protein with an in-frame deletion of 24 amino acids and unknown function 79.
Because of the lack of secretion of mpl-tr, we analyzed whether mpl-tr plays a
physiological role intracellularly. Here we demonstrate that mpl-tr specifically
inhibits TPO-dependent proliferation and survival. We show that mpl-tr is
responsible for initiating protein downregulation of the full-length mpl receptor
by a cathepsin-like cysteine protease activity. As a consequence, the amount
of total mpl protein in the cell is drastically reduced. Further, our data show
that for this effect a short peptide sequence at the C terminus of mpl-tr is
essential. The ability of mpl-tr to antagonize mpl function represents a novel
mechanism by which cytokine signaling is regulated.
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Materials and Methods
DNA constructs
The plasmid pCD4 (pMICD4) is a gift from Dr. Harvey A. Lodish. It contains an intraribosomal
entry site (IRES) followed by a truncated cDNA of the human CD4 gene and is derived from
the retroviral expression vector pMX 104. To generate pCD4-mpl-tr, mpl-tr was cloned into the
restriction sites XhoI and blunted BamH1 of the multiple cloning site of pCD4. For the
generation of the mpl-tr mutants, site-directed mutagenesis was performed using the
QuikChange XL mutagenesis kit (Stratagene, Cedar Creek, TX) according to the
manufacturer’s protocol. The following primers were used:
GAAGGCCGTGAGGACTGGAAGTAGACTGAGGCAAGCTTTGTGG (sense),
CCACAAAGCTTGCCTCAGTCTACTTCCAGTCCTCACGGCCTTC (anti-sense) for the stop
codon in Dpep30; GAAGGCCGTGAGGACTGGAAGAGACTGAGGCAAGCTTTGTGG (sense),
CCACAAAGCTTGCCTCAGTCTCTTCCAGTCCTCACGGCCTTC (anti-sense) for the frame
shift in tr-pepmpl; GCCCTAAGTCCTTCTTAAGGCCACGGTTACCGATAGCTGTG (sense),
CACAGCTATCGGTAACCGTGGCCTTAAGAAGGACTTAGGGC (antisense) for the stop
codon in tr-pepmpl. Mpl, mpl-tr and pep30 cDNAs were cloned into the 5myc-pcDNA1 vector
(gift from Dr. Eva Reinhard, Biozentrum, University of Basel), which contains at its 5’ end a
sequence encoding a HA-signal sequence followed by 5 myc epitopes 105. For stable
transfections, myc-tagged mpl cDNA was cloned into the pGD expression vector 106 as a
XhoI-NotI fragment. For transient transfections into human kidney 293T cells, mouse mpl,
myc-mpl and mpl-tr cDNAs were subcloned into the pcDNA3 expression vector (Invitrogen,
Carlsbad, CA) as XhoI-NotI fragments.
Cell transfection and culture
BaF3 cells were cultured as described 84. UT-7 cells were grown in RPMI 1640 supplemented
with 10% fetal calf serum (FCS) and 2ng/ ml recombinant human GM-CSF (PromoCell,
Heidelberg, Germany). For transfections of BaF3 and UT7 cells, 0.5 – 1 ¥ 107 cells were
electroporated at 270 V and 975 mF at ambient temperature in the presence of 20 mg plasmid.
UT-7/myc-mpl cells were cultured in the presence of 450 mg/ml G418. A pool of stably
transfected UT-7/myc-mpl cells was used for the transfection with different pCD4 constructs.
The BaF3/mpl cell clone used in this study (TM17) has been described 84. The BaF3/mpl
clone TM17 was used for transfections with different pCD4 constructs. Cells expressing
human CD4 were selected by the usage of CD4 microbeads according to the manufacture’s
protocol (Miltenyi, Auburn, CA). For transient transfections of 293T cells, the transfection
reagent FuGENE was used according to the manufacturer’s protocol (Roche, Switzerland).
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Proliferation assay
An XTT proliferation kit (Roche, Switzerland) was used according to the manufacture’s
protocol to determine cytokine-dependent cell proliferation. In brief, cells were plated in 96-
well plates at 104 cells per well in 100 mL of medium containing the indicated concentrations
of cytokine. After 3.5 days of stimulation for BaF3 cells and 5 days of stimulation of UT7 cells,
50 mL of a 1mg/mL stock solution of XTT with 5 mmol/L phenazine methosulfate, an electron
coupling agent, was added to each well. The product of XTT reduction by viable cells,
reflecting the number of cells per well, was measured at 4 hours at 450 nm.
Protein expression analyses
Surface expression of myc-mpl was analyzed by fluorescence-activated cell sorting (FACS)
analysis. For this analysis, 5 ¥ 105 cells were incubated with the mouse monoclonal antibody
9e10 directed against the N-terminal myc-tag of myc-mpl for 60 minutes on ice followed by
incubation with the fluorescein isothiocyanate (FITC)-labeled goat antimouse antibody (BD
Biosciences, San Diego, CA). Untransfected UT7 cells served as a control. Total amounts of
c-mpl and mpl-tr were determined by immunoblot analysis using a rabbit polyclonal antibody
directed against mpl, as described 74. The same polyclonal antibody and 9e10 were used for
the detection of myc-mpl protein by immunoblot analysis. To normalize for protein loading, the
membranes were reprobed using a mouse monoclonal antibody AC-40 directed against actin
(Sigma, St. Louis, MO).
Puls-chase analysis
293T cells cultured in 60-mm dishes were transiently transfected with 3 mg myc-mpl and 3 mg
mpl-tr expressed off the pcDNA3 expression vector. Pulse–chase analysis was begun 40 h
post-transfection. To perform the pulse–chase, cell monolayers were washed twice with warm
phosphate-buffered saline (PBS), and starved of methionine and cysteine by incubation for 40
min at 37°C in 1 ml of methionine/cysteine-free DMEM (Gibco-BRL), supplemented with 5%
dialyzed FCS (Gibco-BRL). Following amino acid starvation, cellular proteins were pulse-
labeled by incubating each plate of cells with 400 mCi of methionine/ cysteine (Tran35S-label;
NEN) for 30 min at 37°C. The radioactive medium was then removed, the cells washed twice
in warm PBS, re-fed with DMEM supplemented with 2 mM methionine and 2 mM cysteine,
and incubated for the indicated times. Cells were collected, and labeled proteins recovered by
denaturing immunprecipitation using the 9E10 antibody and the method of Hofmann et al. 107.
Immune complexes were analyzed on 10% SDS–PAGE gels. The dried gels were quantitated
on a Molecular Imager FX (BIO-RAD, Hercules, CA) using Quantity One software (BIO-RAD,
Hercules, CA).
Apoptosis
For quantification of apoptosis, UT-7/myc-mpl cells were grown at 2 ¥ 105 cells/mL in the
presence of either 2 ng/mL of human GM-CSF or 2 ng/mL or 20 ng/mL of human TPO (gift
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from Dr. Frederic J. de Sauvage). After 48 hours, cells were washed twice and stained with
annexin V with the use of the annexin V-FITC kit (Roche, Switzerland). FITC positive cells
were quantitated by flow cytometry.
Generation of cDNA and Quantitative-Polymerase chain reaction (Q-PCR)
RNA was extracted from cell lines by means of Trizol reagent (Life technologies, Rockville,
MD). RNA was treated with RNase-free Dnase (Promega, Madison, WI) for 90 minutes at
37°C, heat-inactivated and then purified with RNAeasy (Qiagen, Germany) according to
manufactures protocol. For reverse-transcriptase-polymerase chain reaction (RT-PCR), 1mg
of RNA was reverse-transcribed after random hexamer priming in a 30-mL reaction mix
containing 100 U of omniscript RT (Qiagen, Germany). The reaction was performed for 90
minutes at 37°C followed by 30 minutes at 40°C and denaturing at 95 °C for 10 minutes. The
cDNA was diluted 1:10 and used for Q-PCR. The differential quantification of mpl and mpl-tr
was performed on an ABI Prism 7700 sequence detector (Applied Biosystems, Foster City,
CA), as described 1. The sequences for the isoform specific primers and for MGB probes
were as follows: for the exon 10/11 boundary of murine c-mpl:
GCAATTTCCTGCGCACTACA, GGAAGCGAGGGCCACAA, GAGACTGAGGCATGC
(probe); for mpl-tr: AGCGAGGGCCACAAAGC, CAGCTCAAGAGACCTGCTACCA,
CCTCAGTCTCCTTCCAGT (probe). The DCT values were derived by subtracting the
threshold cycle (CT) values for mpl and mpl-tr from the CT value for mouse ribosomal protein
L19 (RPL19), which serves as an internal control 1,108. All reactions were run in duplicates.
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Results
Co-expression of mpl-tr with c-mpl inhibits TPO-dependent mitogenic
and survival signaling. To study the effect of mpl-tr on TPO-dependent
proliferation, we used two cytokine-dependent cell lines for cell growth
assays: the murine cell line BaF3 and the human megakaryoblastic cell line
UT-7. Both cell lines do not express mpl protein endogenously. To assay
potential effects of mpl-tr on the function of the full-length mpl protein, we
used BaF3 cells stably transfected with murine mpl (BaF3/mpl) 84 (Fig.1).
These cells were subjected to a second round of transfection with an
expression vector containing the cDNA for murine mpl-tr. The presence of an
IRES followed by a truncated form of human CD4 in the vector allowed
selection of mpl-tr expressing cells using magnetic anti-CD4 microbeads.
Fig. 1. Schematic representation
of the c-mpl gene and of mpl and
mpl-tr protein. (A) The known
alternate splice variants of human
and mouse c-mpl are depicted in a
schematic drawing of the exon/
intron structure of c-mpl. (B) The
extracellular domain of mpl protein
consists of two cytokine receptor
modules, one proximal and one
distal to the plasma membrane
(PM). A black oval represents the
transmembrane domain and white
boxes the cytoplasmic portion.
Horizontal lines indicate the
position of the conserved cysteines.
The black bars indicate the
positions of the conserved
WGXWS and WSXWS motifs. The
myc-mpl variant  has f ive
consecutive myc epitopes added in
frame to the N!terminus of the
mature mpl protein. The mpl
isoform mpl-t r  lacks  the
juxtamembrane extracellular
portion and the transmembrane
domain. Due to an altered reading
frame, the C!terminus comprises a
stretch of 30 residues of novel
sequence termed pep30.
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Fig. 2. Effect of mpl-tr on proliferation of cytokine-dependent cell lines. We used two cytokine-
dependent cell lines for cell growth assays: the murine IL-3 dependent cell line BaF3 and the human
GM-CSF-dependent cell line UT-7. Both cell lines do not express mpl protein endogenously. Upon
expression of mpl BaF3 and UT-7 cells proliferate in response to TPO. The isoform mpl-tr was
expressed off a retroviral vector containing an IRES followed by a truncated form of human CD4,
used as a quantitative selectable marker. (A) BaF3 cells stably transfected with mpl (BaF3/mpl) were
additionally transfected with pCD4 or pCD4-mpl-tr and sorted with anti-CD4 microbeads.
Proliferation of transfected and parental BaF3 cells was determined by a XTT assay with increasing
concentrations (ng/ml) of IL-3 or TPO, as indicated. Error bars indicate the standard deviation on
triplicate samples. (B) UT-7 cells stably transfected with myc-mpl (UT-7/myc-mpl) were additionally
transfected with pCD4 or pCD4-mpl-tr and sorted with anti-CD4 microbeads. Proliferation of
transfected and parental UT-7 cells in the presence of GM-CSF and TPO is shown. Annotation as
above. (C) BaF3/mpl cells were were cultured with increasing concentrations (ng/ml) of IL-3 or TPO
in the presence of mpl-tr conditioned media (filled diamonds) or control media (open diamonds).
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This procedure was repeated 3-4 times to enrich for CD4 positive cells and
expression of CD4 was confirmed by flow cytometry (data not shown). The
sorted cells were cultured with different concentrations of either
IL-3 or TPO. As expected, parental BaF3 cells failed to respond to TPO (Fig.
2A). On the other hand, BaF3/mpl cells and BaF3/mpl cells transfected with
the parental pCD4 plasmid proliferated in dependence on TPO concentration.
In contrast, BaF3/mpl cells expressing mpl-tr failed to show a proliferative
response to TPO, behaving similar to parental BaF3 cells. Importantly, mpl-tr
did not have a general inhibitory effect on proliferation, because in the
presence of IL-3, BaF3/mpl cells expressing mpl-tr grew as efficiently as
control cells. The same result was obtained when mpl-tr was expressed in
human UT-7 cells that were stably transfected with mpl. In this experiment we
used a mpl construct with 5 myc-tags at the N terminus (UT-7/myc-mpl) (Fig.
1). The myc-mpl protein conveyed TPO-responsiveness to UT-7 cells,
demonstrating that the myc-tag did not interfere with mpl function (Fig. 2B).
When mpl-tr was expressed in UT-7/myc-mpl cells, TPO-mediated
proliferation was abolished, but GM-CSF-dependent proliferation remained
unchanged. To test whether the observed inhibitory effect could be mediated
by secreted mpl-tr protein, medium conditioned by mpl-tr-expressing cells was
transferred onto BaF3/mpl cells. TPO-dependent proliferation of BaF3/mpl
cells was not inhibited by the presence of this conditioned media (Fig. 2C)
demonstrating that no secreted inhibitory activity exists. Since mpl signaling
exerts an anti-apoptotic effect, we analyzed the effect of mpl-tr on TPO-
dependent cell survival. UT-7/myc-mpl cells transfected with either mpl-tr or
control vector were cultured with GM-CSF or with TPO. After 48 hours, cells
were incubated with annexin V and analyzed by flow cytometry. In the
presence of GM-CSF, mpl-tr had no effect on the number of annexin V-
positive cells. However, with TPO, most cells co-expressing mpl and mpl-tr
stained positive for annexin V (Fig. 3). This indicates that mpl-tr expression
inhibits the anti-apoptotic signal delivered by TPO.
Mpl-tr mediates downmodulation of mpl protein expression in a post-
transcriptional manner. To investigate the inhibitory mechanism exerted by
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mpl-tr, we analyzed the effects of mpl-tr on mpl protein expression. First, we
asked whether mpl protein surface expression was affected by the presence
of mpl-tr. Cells were stained with anti-myc antibodies (Fig. 4A). As expected,
Fig. 3. Effect of mpl-tr on cell
survival. UT-7/myc-mpl cells were
transfected with pCD4 (open bars) or
pCD4-mpl-tr (black bars) and sorted
with anti-CD4 microbeads. Cells were
cultured in the presence of GM-CSF or
TPO at the indicated concentrations for
48 hours, stained with FITC-labeled
annexin V and analyzed by flow
cytometry. The results of 3 independent
experiments are shown. Error bars
indicate the standard deviation.
Fig. 4. Analysis of mpl protein expression
in UT-7 cell line. (A) UT-7/myc-mpl cells
stably transfected with pCD4 (thick line) or
pCD4-mpl-tr (thin line) or the parental UT-7
cells (dotted line) were incubated with the
mouse monoclonal anti-myc antibody 9E10
and a secondary FITC-labeled goat anti-
mouse antibody to detect myc-mpl on the
plasma membrane. Cells were analyzed by
flow cytometry and one representative result
is shown. (B) The same UT-7/myc-mpl cells
transfected with pCD4 or pCD4-mpl-tr as in
(A) were cultured either on 2ng/ml GM-CSF
or 2ng/ml TPO for 24 hours and total mpl
protein expression in total cell lysate was
determined by immunoblot analysis. Proteins
of 93 kDa corresponding to myc-mpl and of
55 kDa for mpl-tr were detected. The same
membrane was probed for actin to control for
equal loading. To determine an effect of mpl-
tr on mpl mRNA expression, the amount of
myc-c-mpl mRNA was determined by
Q-PCR. The DCT values were derived by
subtracting the threshold cycle (CT) values
for c-mpl from the CT value for RPL19,
which serves as an internal control. All
reactions were run in duplicates. The DCT
values are shown underneath the
corresponding lanes. (C) 293T cells were
transiently transfected with myc-mpl or
transiently co-transfected with myc-mpl and
mpl-tr or control plasmid, respectively.
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UT-7/myc-mpl cells showed marked myc-mpl surface expression. In contrast,
the staining of UT-7/myc-mpl cells expressing mpl-tr did not significantly differ
from the control staining of the parental UT-7 cells, indicating that mpl-tr
interferes with myc-mpl cell surface expression. We then asked whether the
lack of detectable myc-mpl surface expression correlated with a decrease in
total myc-mpl protein. Immunoblot analysis of total cell lysates demonstrated
a massive reduction of myc-mpl protein in cells that expressed mpl-tr (Fig.
4B). The decrease in myc-mpl protein was observed irrespective of whether
the cells were grown with TPO or GM-CSF. Importantly, mpl-tr did not alter
mpl mRNA levels, as indicated by the unchanged DCT values for mpl (Fig.
4B). Expression of mpl-tr also led to a dramatic decrease in expression of the
untagged mpl protein in BaF3/mpl cells without affecting mRNA levels
showing that mpl-tr targets mpl protein regardless of the presence of an
N-terminal myc-tag (Fig. 6C). To determine whether this phenomenon was
limited to hematopoietic cells, we performed transient co-transfections of mpl
and mpl-tr cDNAs into human 293T cells. As shown in Fig. 4C, expression of
mpl-tr in 293T cells lowered the amount of mpl protein without altering mpl
mRNA expression.
Mpl-tr mediates dose-dependent reduction of mpl protein expression
and a decrease of mpl protein half-life while steady-state levels of mpl-tr
remain unchanged. To quantify the effect of mpl-tr on mpl expression, we
transiently co-transfected 293T cells with a constant amount of plasmid
encoding mpl and varying amounts of plasmid for the expression of mpl-tr. In
this experiment mpl protein amount was affected by mpl-tr in a dose-
dependent manner (Fig.5 A). Measuring mRNA levels by Q-PCR confirmed
that mRNA expression correlated with the amount of plasmid DNA
transfected. For example, the mpl-tr (DCT) value for cells transfected with 0.1
mg of mpl-tr was –4. Cells transfected with 30 times the amount of mpl-tr (3
mg) had a mpl-tr (DCT) value of –9. This corresponds to a decrease of 5 CTs
which equals 25 = 32 times higher expression of mpl-tr (Fig.5 A).
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Fig. 5. Dose response, protein turnover, and sensitivity to protease inhibitors of mpl
downregulation. (A) 293T cells were transiently co-transfected with varying amounts of plasmid
DNA encoding mpl and mpl-tr (numbers above the lanes indicate DNA amount in mg). Mpl,
mpl-tr and actin proteins were detected by immunoblot analysis. The mRNA expression of c-mpl
and c-mpl-tr was determined by Q-PCR: DCT values for mpl and mpl-tr are shown below the
corresponding lanes of the immunoblots. The amount of mpl DNA was kept constant while the
amount of mpl-tr DNA varied. (B) In this experiment, mpl DNA was varied and the amount of
mpl-tr DNA was kept constant. (C) Pulse-chase analysis of the turnover of myc-mpl protein in
the presence and absence of mpl-tr. 293T cells transiently transfected with pcDNA3-myc-mpl
alone (-) or in combination with pcDNA3-mpl-tr (+ mpl-tr) were metabolically labeled with of
(48) methionine/ cysteine and then chased in the presence of excess cold methionine and cysteine
for 3, 6, 9, and 12 h. The amount of labeled myc-mpl was determined by immuno-precipitation
with 9E10 and SDS-gel analysis. (D) UT-7/myc-mpl cells stably transfected with pCD4-mpl-tr
were treated with protease inhibitors at a final concentration of 25 mM each or DMSO as
indicated. After 6-8 hours of incubation, total cell lysates were subjected to immunoblot analysis.
(E) UT-7/myc-mpl cells stably transfected with pCD4 were treated as described for the pCD4-
mpl-tr transfected cells. (F) 293T cells were transiently co-transfected with mpl and mpl-tr and
then treated with CATI-1 or DMSO for 6-8 hours.
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In the converse experiment, we transfected 293T cells with a constant amount
of mpl-tr and varied the concentration of mpl. We found that steady-state
expression of mpl-tr was not altered by the presence of increasing
amounts of mpl (Fig. 5B). Since mpl-tr affects the steady state levels of mpl
protein, we determined the half-life of mpl by a pulse-chase experiment (Fig.
5C). In the presence of mpl-tr, the half-life of mpl was decreased from 5-6
hours to 2-3 hours (Fig. 5C).
The cysteine cathepsin inhibitor I (CATI-1) restores mpl protein
expression in the presence of mpl-tr. To identify the mechanism that
underlies diminished mpl protein expression in the presence of mpl-tr, we
treated mpl-tr transfected UT-7/myc-mpl cells with the cathepsin inhibitor
CATI-1, the proteasome inhibitor MG132 or the calpain inhibitors ALLN or
EST. Inhibitors were added at a final concentration of 25 mM each and cells
were cultured for 6-8 hours in the presence of GM-CSF. Only CAPI-1 restored
Fig. 6. Functional analysis of the
C-terminal peptide of mpl-tr. (A)
Schematic draw of mpl-tr protein and
two mpl-tr mutants used in this study.
The amino acid sequence of the
junction and the C-terminal 30 amino
acids are shown. In the tr-Dpep30
mutant, all C-terminal 30 amino acids
of mpl-tr are removed. In the tr-pepmpl
mutant, the pep30 peptide is replaced
by 30 amino acids derived from the
mpl reading frame of exon 11. (B)
Proliferation of BaF3/mpl cells stably
transfected with pCD4 (open square),
pCD4-mpl-tr (filled triangle), pCD4-
Dpep30 (open triangle), and pCD4-tr-
pepmpl (filled diamond) in the
presence of increasing concentrations
of IL-3 or TPO (numbers indicate
concentration in ng/ml). Error bars
indicate the standard deviation. (C)
Immunoblot analysis of total lysates
from the same cells as in (B).
Expression of mpl mRNA is
indicated by the DCT values below the
corresponding lanes.
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mpl protein expression (Fig. 5D), a weak mpl band was detectable with
MG132 treatment, whereas the other inhibitors had no effect. None of the
inhibitors changed the steady-state mpl protein levels in the UT-7/myc-mpl
cells lacking mpl-tr (Fig. 5E).  To confirm these results in a different cell
system, we also treated 293T cells with CATI-1 and determined mpl protein
expression. Similar to UT-7/myc-mpl, 293T cells co-transfected with mpl and
mpl-tr showed a rescue of mpl protein expression in the presence of CATI-1
(Fig. 5F). These results argue that mpl-tr mediates mpl protein degradation by
a cathepsin-like protease activity.
The C-terminal peptide sequence of mpl-tr is necessary but not
sufficient for the inhibition of cell proliferation and for mpl protein
degradation. The amino acid sequence of mpl-tr is identical to the N terminus
of mpl except for a stretch at the C terminus of mpl-tr, 30 amino acids in
length (Fig. 1). We therefore speculated that this unique C-terminal peptide in
mpl-tr could be of functional importance. To test this hypothesis, we made two
mutants of mpl-tr: in the first mutant, Dpep30, we introduced a stop codon at
position 427, removing the entire C-terminal peptide (Fig. 6A). In the second
mutant, tr-pepmpl, the sequence of the C-terminal peptide was changed by
adding two base pairs, which restored the reading frame of full-length mpl and
by introducing a stop codon terminating the reading frame after 30 amino
acids (Fig. 6A). With these mpl-tr mutants we stably transfected BaF3/mpl
cells and assayed TPO-dependent proliferation. As shown in Fig. 6B, only
mpl-tr abrogated mpl-mediated cell growth, whereas tr-Dpep30 and tr-pepmpl
did not interfere with TPO-dependent proliferation. As expected, the mpl-tr
mutants did not interfere with the proliferative responses to IL-3 (Fig. 6B).
Immunoblot analysis showed that Dpep30 and tr-pepmpl were expressed at
levels similar to mpl-tr (Fig. 6C). This indicates that the degree of expression
does not explain the failure of the mutants to inhibit TPO-dependent growth.
Importantly, the levels of mpl protein in cells expressing the mpl-tr mutants
were similar to BaF3/mpl control cells, but mpl was undetectable in cells
expressing mpl-tr.
Results I 38
These results demonstrate that the C-terminal peptide sequence from mpl-tr
is required for the ability of mpl-tr to promote a decrease in mpl protein and to
inhibit TPO-dependent cell proliferation. Furthermore, these results illustrate
that the function of mpl-tr in growth inhibition directly correlates with its role in
mpl protein reduction. To determine whether pep30 is sufficient to interfere
with TPO-induced proliferation and to mediate mpl degradation, we generated
a myc-tagged versions of pep30 and mpl-tr (Fig. 7A). Myc-pep30 did not affect
TPO-dependent proliferation (Fig. 7B) nor alter the expression levels of mpl
protein (Fig. 7C), whereas myc-mpl-tr behaved comparable to untagged mpl-
tr. Thus, pep30 sequence alone is not sufficient to inhibit mpl function.
Fig. 7.  Pep30
sequence alone is
not sufficient to
i n h i b i t  m p l
funct ion.  (A)
Schematic drawing
of myc-tagged
pep30 and mpl-tr
(not to scale). (B)
Proliferation of
BaF3/mpl cells
expressing vector
alone (pCD4),
myc-pep30 a n d
myc-mpl-tr. (C)
Immunoblot of
total cell lysates
probed with anti-
myc (9E10), anti-
mpl and anti-actin
antibodies.
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Discussion
Alternatively spliced cytokine receptor variants are emerging as regulators of
cytokine signaling 36-38,68,109,110. The c-mpl locus gives rise to the full-length
mpl protein and the mpl-tr isoform, which is present in both human and mouse
72,74,77. Here, we characterized mpl-tr as a specific inhibitor for TPO-
dependent proliferation and described a novel mechanism of receptor protein
downmodulation mediated by an alternate isoform of the same receptor
through a cathepsin-like protease activity.
Alternatively spliced isoforms are frequently found among members of the
cytokine receptor superfamily and most family members have been shown to
be capable of giving rise to soluble forms 63. So far, two functions have been
assigned to soluble cytokine receptor isoforms: soluble receptors can prolong
the half-life of the ligand and activate signal transduction by associating with a
transmembrane receptor complex, as exemplified by the soluble IL-6 receptor
111,112. Alternatively, soluble receptors can act as antagonists of their
membrane-bound counterparts by binding and neutralizing the ligand, e.g. IL-
5 or GM-CSF 65,66,113,114. In either model, the function of the soluble receptor is
dependent on its secretion. However, the serum levels of some soluble
receptor are low or undetectable 63,115, suggesting additional functions of
soluble receptors as non-secreted forms.
Because the deletion in mpl-tr removes the transmembrane domain, mpl-tr is
expected to give rise to a secreted form, which might antagonize mpl
signaling by sequestering TPO. However, this model cannot explain the
observed dominant-negative effect of mpl-tr for three reasons: 1) mpl-tr could
not be detected in the cell supernatant 74; 2) high concentrations of TPO did
not titrate out the effect of mpl-tr (Fig. 2); and 3) media conditioned by mpl-tr
expressing cells did not affect TPO-dependent growth of BaF3/mpl cells (Fig.
2C).
We demonstrated that over-expression of mpl-tr leads to a dramatic decrease
in mpl protein amounts, which can explain the dominant negative effect of
mpl-tr on TPO-dependent cell proliferation and survival. The decrease in mpl
protein was not due to differences in c-mpl mRNA expression (Fig. 4 and 5). A
Results I 40
specific inhibitor for cysteine protease cathepsins, CATI-1, can counteract the
effects of mpl-tr and restore full-length mpl protein expression. In contrast,
inhibitors of Ca2+-dependent cysteine proteases, ALLN and EST, had no
detectable effect on mpl protein amounts. It is therefore tempting to speculate
that in the presence of mpl-tr, mpl traffics to the lysosome where it is
degraded. The small increase in mpl expression in the presence of the
proteasomal inhibitor MG132 may be explained by the finding that some
receptor trafficking events from endosomes to lysosomes require a functional
proteasome 116,117.
The observed effects of mpl-tr appear to specifically target the mpl protein,
since IL-3 and GM-CSF dependent cell proliferation and survival were not
affected. This specificity could be based on an inherent capability of the
extracellular domains of cytokine receptors to form dimers. It has been shown
by crystallography that Epo-R form dimers in the absence of ligand 19. In
analogy to the structure-function studies performed for Epo-R, we expect that
the extracellular portion of mpl-tr is sufficient to allow hetero-dimerization with
the full-length form of mpl. So far, we have been unable to detect this physical
interaction through co-immunoprecipitation (data not shown), possibly
because the interaction is only transient.
We demonstrated that the unique sequence at the C terminus of mpl-tr is
essential for mediating mpl degradation. In one possible scenario, the
C terminus of mpl-tr prevents the secretion of mpl-tr and directs the putative
mpl/mpl-tr dimer to traffic along the endosomal-lysosomal route. Increasing
acidification of the endosomal vesicle could cause the hetero-dimer to
disassemble allowing mpl-tr to be recycled. This model would explain why
mpl-tr protein expression is apparently not affected by the presence of mpl
protein (Fig. 5B). Further structure function analysis the C-terminal sequence
of mpl-tr should allow us to define a minimal functional peptide motif.
Alternatively, mpl-tr may interfere with proper folding of mpl. In both
mammalian cells and in yeast it has been shown that a post-ER quality control
mechanism appears to be responsible for targeting and lysosomal/ vacuolar
degradation of misfolded membrane proteins 118-121. The presence of a
cytosolic portion may be a prerequisite for the detection of partly unfolded mpl
by the post-ER quality surveillance system. Since mpl-tr only contains the
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luminal portion of mpl, it may evade detection by the quality control system.
This would explain why mpl-tr steady state levels are not altered in the
presence of full-length mpl.
Cytokine receptor variants may be important in the regulation of receptor
function. Interestingly, Nakamura et al. demonstrated that transgenic mice
overexpressing the intracytoplasmic truncated erythropoietin-receptor isoform
EpoR-T reveal mild anemia 109. Because overexpression of EpoR-T
diminishes the number of erythrocytes in the mouse, these results suggest a
role of cytokine receptor variants as regulators of proliferation and
differentiation in vivo.
In this study, we have demonstrated that an alternate mpl isoform (mpl-tr)
exerts a dominant negative effect on proliferation and survival. Because mpl-tr
is an abundant c-mpl splice variant accounting for about 30% of total mpl
mRNA in mouse spleen 74, mpl-tr is likely to play a physiological role in
megakaryopoiesis. Differential expression has been shown for alternatively
spliced isoforms of cytokine receptors like IL-5 receptor and GM-CSF receptor
110,122. The relative expression of different isoforms of the same cytokine
receptor can determine cell differentiation and cell lineage expansion 110,123. In
analogy to isoforms of other receptors, we speculate that the relative
expression of c-mpl-tr varies with different cell types and developmental
stages and that this serves to modulate mpl function.
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Abstract
Multiple mechanisms for the downmodulation of cytokine receptor signaling
are known. These include post-translational modifications of JAK and STAT
molecules, dephosphorylation of receptor tyrosines and the effects of
dominant-negative cytokine receptor isoforms. Thrombopoietin (TPO) and its
receptor c-mpl are essential for normal megagkaryopoiesis and play an
additional role in regulating hematopoietic stem cell numbers in vivo. We have
recently characterized the alternate mpl variant mpl-tr as a dominant-negative
isoform, which specifically inhibits TPO-dependent cell proliferation and
survival signaling. To test for the in vivo function of alternative mpl isoforms,
we generated mice expressing full-length mpl as a transgene in a mpl
knockout background. These mice express mpl full-length as the only mpl
isoform and develop severe thrombocytosis with platelet numbers, elevated
about five times higher than normal. The reintroduction of the endogenous
mpl allele restores normal platelet counts and we attribute this to the in vivo
effect of dominant-negative mpl isoforms. A mpl knock-in allele, which does
not express mpl-tr but still expresses the second known alternate variant of
murine mpl, mpl-II, normalizes platelet numbers, similar to the endogenous
mpl allele.  This result demonstrates that the absence of mpl-tr is not sufficient
to cause thrombocytosis. We propose that mpl-II is an additional dominant-
negative mpl isoform and attenuates the expansion of the megakarocytic
lineage in vivo.
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Introduction
Of the many cells in the body, the hematopoietic cells are among those with
the highest rate of self-renewal and turnover. The production and destruction
of these cells are tightly controlled by a number of hematopoietic growth
factors. Interestingly, many of these hematopoietic growth factors have
primarily lineage-restricted effects as demonstrated in knockout analyses. For
example, gene deletion of erythropoietin (EPO) or of its receptor Epo-R lead
to a specific reduction in erythrocytes 124-126. Similarly, the disruption of G-CSF
and G-CSF-R expression solely affects granulopoiesis 127-129. Finally,
thrombopoietin (TPO) and TPO-R deficiencies result in a profound reduction
of platelet and bone marrow megakaryocyte numbers, but do not significantly
alter megakaryocyte differentiation 82,130,131. Although it is clear that the
primary function of TPO is to regulate platelet numbers, several lines of
evidence indicate that this cytokine modulates multiple aspects of
hematopoiesis. Importantly, all hematopoietic stem cells (HSC) are positive
for mpl expression and genetic elimination of mpl reduces the numbers of
murine HSCs by 7-8 fold 86. In humans, null mutations in mpl lead to
congenital amegakaryocytic thrombocytpenia, a disorder that almost
invariably leads to aplastic anemia 132-134. Together, these findings suggest
that mpl activity supports mostly the expansion of HSC and megakaryocytic
precursors, but has little importance in megakaryocytic differentiation. In this
context, it is worthwhile remembering that the c-mpl gene was first discovered
as the cellular homolog of the retroviral oncogene v-mpl 71,72,74, emphasising
the primary role of mpl as a transducer of a proliferation signal. Because
cytokines like mpl are potent growth factors, stringent mechanisms of signal
attenuation are essential for ensuring an appropriate, controlled cellular
response. Several protein tyrosine phosphatases including SHIP-1, CD45,
and PTP1b have been shown to be negative regulators of cytokine signaling
62,135. Members of the suppressor of cytokine signaling (SOCS) family of
proteins act in a negative feedback loop, inhibiting the cytokine activated
Janus kinase/ signal transducers and activators of transcription (JAK/ STAT)
signaling pathway to modulate cellular responses 136. Thirdly, protein
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inhibitors of activated STAT (PIAS) bind activated STAT dimers and block
transcription in a process that may involve sumoylation of STATs 57.
An additional mechanism of modulating the cytokine response is the
expression of alternative cytokine receptor variants, which act as dominant-
negative isoforms 68,109,137. Mechanistically, dominant-negative receptor
variants can form non-functional heterodimers with the full-length receptor or,
when expressed as secreted ‘soluble’ isoforms, compete with the receptor for
ligand binding 63. We have recently discovered a third mechanism, in which
the mpl isoform mpl-tr mediates protein degradation of the full-length receptor
by a cathepsin-like cysteine protease activity (Coers et al., in press).
Altered expression of alternative spliced mRNA variants has been linked to a
number of diseases 138. We were therefore interested in determining whether
mpl isoforms are important for normal megakaryopoiesis. To address this
question we generated mice which express c-mpl under the control of the mpl
promoter in a mpl knockout background, thereby deleting all alternate
isoforms while retaining full-length mpl receptor expression. These mice have
platelet numbers elevated five fold compared to wild type and show additional
characteristics which are reminiscent of human essential thrombocythemia
(ET), a myeloid disorder characterized by a persistent increase in circulating
platelets. Expression of the endogenous mpl allele in these thrombocthemic
mice restores the wild type phenotype, showing that the mpl allele contains a
dominant-negative property. A mpl knock-in allele, which does not express
mpl-tr but retains expression of the alternate isoform mpl-II 80, acts similar to
the endogenous mpl allele in reducing the number of platelets. This
demonstrates that an additional dominant-negative mpl isoform other than
mpl-tr must exist and we propose that this isoform is the recently described
mpl variant mpl-II.
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Materials and Methods
Generation of transgenic mice
To generate the transgenic construct, a 2kb Hind III-Apa I promoter fragment was isolated
from a lambda FIX II genomic DNA library and subcloned into pKS II. The mpl cDNA was
added as a blunt ended fragment into an EcoRV site. At the 3’ end an SV40 polyadenylation
signal was added. The transgenic construct was excised as a Xho I-Not I fragment. The
resulting 5kb fragment, which contains no vector sequences, was used for oocyte
microinjection. We have generated 5 transgenic founder mice in the B6D2F1 strain (BRL,
Switzerland) by standard oocyte injection.
Blood and tissue analysis
Blood was obtained by cardiac puncture without anticoagulants. Approximately 500 ml of
blood was immediately mixed with EDTA and blood counts were performed with an
automated blood counter (Technicon H-3, Bayer Diagnostics, Tarrytown, NY). For mouse
TPO ELISA (mouse TPO Quantikine kit, R&D Systems), the remaining blood was either also
mixed with EDTA to obtain plasma or allowed to coagulate and serum was collected. For
histology, freshly dissected tissues were fixed in Optimal*Fix (American Histology Reagent
Co., Stockton, CA). Fixed specimens were embedded in paraffin, sectioned, and stained by
the Transgenic Pathology laboratory at the University of California at Davis. Megakaryocyte
frequency was determined by two-color flow cytometry as described in (Arnold et al., 1997).
In brief, bone marrow cells from one femur and one tibia were isolated in CATCH (0.84 mM
adenosine, 2 mM theophilline, 0.38% sodium citrate, 3.5 % BSA and   mM Hepes in Hanks
BSS (GIBCO) at pH 7.0). Cells were filtered through a 100 mm nylon mesh. Megakaryocytic
cells were stained using the monoclonal 4A5 rat anti-mouse platelet antibody and a Tago
FITC–goat anti rat IgG F(ab’)2 antibody. Staining was performed for each antibody at 4°C for
30 minutes. Samples for electron microscopy were processed essential as described 139. In
brief, spleen tissue was diced into pieces of roughly one square millimeter fixed for 1 hour in
3% glutaraldehyde in 0.1 mol/L phosphate buffer, pH 7.4, washed, and embedded in Epon.
Ultrathin sections were collected on grids and imaged using a Philips Morgani 268D electron
microscope. Representative fields of sections performed on the entire samples were chosen
for illustration.
Clonal culture of hematopoietic progenitors
Clonal cultures of hematopoietic cells were performed as described 140. Briefly, to assay for
myeloid and granulocytic progenitors, 5x104 bone marrow cells for wild type and knockout
animals or 2.5x104 bone marrow cells for transgenic animals were placed in 0.3% agar in
Iscove’s modified Dulbecco’s medium (IMDM) supplemented with 20% horse serum and
10mg/ml BSA (Boehringer Mannheim) and stimulated with Hemostim M2100 at a final
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concentration of 2% (StemCell Technologies, Inc.) and 100ng/ml human G-CSF (Roche).
These conditions resulted in optimal stimulation of neutrophil (G), neutrophil-macrophage
(GM), and macrophage (M) colony forming cells. To assess the number of megakaryocytic
(Meg) progenitors, 2x105 and 1x105 bone marrow cells, respectively were grown in 0.3% agar
under serum free conditions 140 and were stimulated with 2% Hemostim M2100 and 10% of
serum free conditioned media of a TPO expressing NIH/3T3 cell line 84. Finally, to assess
erythroid colony growth 5x104 and 2.5x104 bone marrow cells were cultured in 2.7%
methylcellulose in IMDM supplemented with 20% fetal bovine serum (FBS) and 1mg/ml BSA
and stimulated with 2% Hemostim M2100 and 2.7 U/ml EPO (Eprex). The cultures were
incubated for 7 days at 37°C in a humidified atmosphere with 5% CO2. Myeloid, granulocytic
and erythroid colonies were scored for morphology, whereas CFU-Meg were identified using
a histochemical staining for acetylcholinesterase. Colonies containing at least five
acetylcholinesterase positive cells were scored as CFU-meg 141.
RNA isolation and ribonuclease protection assay
Spleen tissue was homogenized in 4 M guanidium isothiocyanate with a Polytron
homogenizer and RNA samples were prepared by the acid phenol method 142. For
ribonuclease (RNase) protection analysis 143, we constructed a riboprobe for the detection of
the transgenic and the endogenous mpl mRNA by subcloning a 368 bp PCR fragment of
mouse mpl cDNA into pBluescript. As primers we used 5’-CTCGCTTCCAGACCTACACC-3’
and 5'-GGATAAGGTAGT GTGTAGGA-3'. The resulting vector was digested with Hind III,
transcribed with T7 RNA polymerase and hybridized to 30mg of total RNA at 50°C as
described 143. This riboprobe protects a 368 nucleotides (nt) fragment for the endogenous mpl
cDNA and a shorter 318 nt fragment for transgenic mpl transcripts. RNA loading was
normalized with a riboprobe for mouse hypoxanthine-guanine phosphoribosyl transferase
(HPRT), a house keeping gene. A. Sca I – Hind III fragment representing nucleotides 679 to
840 of mouse HPRT cDNA 144 was subcloned into pBluescript. This probe protects a 161 nt
fragment. HPRT riboprobe was mixed with the mpl riboprobe and added as an internal
standard to each sample. Protected fragments were separated on 6% polyacrylamide / 8M
urea sequencing gels. Dried gels were exposed to phosphorimager screens and quantitations
of radioactive bands were performed on a phosphorimager 425 using the ImageQuant
software (Molecular Dynamics Inc., Sunnyvale, CA).
Platelet and megakaryocyte isolation
For platelet isolation, blood was drawn by cardiac puncture into a syringe containing 3,8%
Citrate. Platelet rich plasma (PRP) and afterwards pure platelets were isolated by
centrifugation at 350g and 1300g, respectively, for 10 minutes. Platelets were then washed
with PBS and purity was determined by automated blood counter (Technicon H-3, Bayer
Diagnostics, Tarrytown, NY). For megakaryocyte isolation, two femurs per mouse were
flushed with CATCH medium (129 mM NaCl, 8.614 mM Na2HPO4, 1.6 mM KH2PO4, 0,4% Na-
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citrate, 11.1 mM glucose, 1mM adenosine, 2 mM theophilline, 2.3 mM PGE1 and 1% BSA).
4ml of a single bone marrow cell suspension was then mixed with 3 ml of Percoll/ PBS
(1.02g/ ml, Pharmacia), gently layered on top of 4 ml Percoll/ PBS (1.05 g/ml, Pharmacia) and
spun for 20 minutes at 400g. The interface was then collected and washed with CATCH
buffer. Finally the purity of the megakaryocyte preparation was assessed by acetylcholine
esterase stain of a cytospin.
Protein expression in platelets and megakaryocytes
Isolated platelets and megakaryocytes were lysed by boiling 5 minutes at 94° C in 2xSDS
Page loading buffer at a concentration of 2x106 platelets/ml and 50'000 megakaryocytes/ ml.
Protein lysates were then separated by SDS Page and transferred to nitrocellulose by
Western Blot. The membranes were blocked with 4% non-fat dry milk in PBS/ 0.05% Tween
20 and incubated overnight at 4°C with 1:5'000 diluted biotinylated monoclonal mouse anti
mpl antibody (kindly provided by F. de Sauvage). After three washes with PBS/ 0.05% Tween
20 the membranes were incubated with 1:1000 diluted horseradish peroxidase-coupled
streptavidine and washed. Enhanced chemiluminescence (ECL) was detected following the
instructions of the manufacturer (Amersham, Buckinghamshire, England). Before reprobing
the membranes were stripped for 30 minutes at 50°C in 62.5 mM Tris HCl (pH 6.8), 2% SDS,
100mM b-mercaptoethanol, blocked in 4% non-fat dry milk and incubated with biotinylated
4A5 rat anti-mouse platelet monoclonal antibody.
Results I 49
Results
Generation of transgenic mice expressing full-length mpl. To assess the
contribution of alternate mpl isoforms to megakaryopoiesis and platelet
production in vivo, we have generated transgenic mice expressing full-length
mpl in a mpl knockout background. The transgenic construct consists of a 2kb
mpl promoter, which directs expression specifically to the megakaryocytic
lineage 145, murine mpl cDNA and an SV40 polyadenylation signal at the 3’
end of the constructs for stability of the construct (Fig. 1A). The construct was
then injected into oocytes. We obtained five founders and detected mpl
transgene (mpl-TG) expression in three (Table 1). These mice are viable,
fertile and show no overt abnormalities. They were then backcrossed into the
mpl knockout background.
Analysis of transgene expression in mouse tissues. To verify that the mpl-
TG was expressed properly, we isolated RNA from mouse spleens. To
distinguish between the mpl-TG and endogenous mpl, an RNase protection
assay was performed. The riboprobe protects a 368 nt fragment for the
endogenous mpl transcrpt and a shorter 318 nt fragment for the mpl-TG
transcript (Fig. 1B). RNA loading was normalized with a riboprobe for mouse
hypoxanthine-guanine phosphoribosyl transferase (HPRT), a house-keeping
gene. Fig 1C shows that the mpl-TG is expressed at levels comparable to
endogenous mpl in non-transgenic wild type controls. To our surprise we
could also detect endogenous mpl mRNA in mpl knockout mice. This is
explained by the gene-targeting strategy used for the generation of these
mice, which consisted of an insertion of a neo-casette in exon 3 of mpl 82.
Further analysis showed that the mpl mRNA expressed in these mpl knockout
mice lacks exons 1 and 2 of mpl (data not shown), which are upstream of the
neo-cassette insertion. It is therefore likely that the mpl mRNA found in these
mice is expressed off the promoter of the neo-cassette. When tested for
proper targeting, protein expression and responsiveness to TPO, these mice
proved to be true knockouts81 (and data not shown).
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Fig. 1. Transgene expression (A) A 2kb Hind III-Apa I mpl promoter fragment
drives the expression of the mpl TG. (B) To distinguish between the TG and
endogenous mpl, an RNase protection assay was performed. The riboprobe protects a
368 nt fragment for the endogenous mpl cDNA and a shorter 318 nt fragment for
transgenic mpl transcripts. (C) RNA from mouse spleen tissue of the indicated
genotpye was used for an RNase protection assay. Protected fragments corresponding
to endogenous mpl and mpl TG mRNAs are depicted. Loading was normalized with a
riboprobe for mouse HPRT. (D) Immunoblotting blotting for mpl protein in isolated
megakaryocytes.
number of TG strains number of strains expressing
the TG
platelet count on mpl ko/ko
background (x 106 /ml)
a                b             b
5 3 5034          6165       3367
Table 1. Five transgenic founder mice were obtained after oocyte injection. Three of
the five resulting mouse strains tested positive for TG expression and were
backcrossed into the mpl ko/ko background. All three lines had clearly elevated
platelet numbers.
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Next, we isolated megakaryocytes from the bone marrow of mpl-TG mice and
wild type controls. In Western blot analysis a strong signal of approximately
80 kDa was detected in wild type megakaryocytes, as expected. This band
was absent in the knockout (Fig. 1D). As observed in Fig.1D, the transgenic
version of mpl protein is expressed at levels similar to the non-transgenic wild
type molecule in megakaryocytes.
Fig. 2 Platelet counts and megakaryocytic precursors in transgenic mice. (A)
Platelet counts in circulating blood from wild type (wt), and transgenic (TG) and non-
transgenic mpl (-) knockout mice (ko/ko). (B) Frequency of megakaryocytes in bone
marrow from the same mice was determined by flow cytometry. (C) CFU-Meg assays
were performed to determine the number of megakaryocytic precursors.
Blood cell counts and progenitor analysis. To investigate the effect of the
removal of alternate mpl isoforms on the production of platelets, complete
blood cell counts were performed. While the absence of mpl in knockout mice
leads to a 90% reduction in platelet count 82,83, mice expressing the full-length
receptor as a mpl-TG in the mpl knockout background have elevated platelet
levels compared to wild type mice (Fig. 2A and Table 1). The presence of the
mpl-TG leads to a five fold increase in platelet numbers compared to normal.
Similarly, the megakaryocyte percentage (Fig. 2B) and the frequency of
megakaryocytic precursors (Fig. 2C) in the bone marrow is increased in
transgenic animals. The aberration in cell numbers is restricted to the
megakaryocytic lineage and circulating blood cell numbers are otherwise
normal (Table 2). Further, we found that all the hematopoietic progenitor
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numbers are elevated in TG-mpl expressing mice compared to the wild type
control (Table 3). This increase in progenitor frequency in the transgenic mice
is probably due to mpl expression on hematopoietic stem cells, as previously
described 86,146. Consequently, enhancement of the HSC pool through mpl-TG
signals can explain the increase in progenitor numbers. The expression off
the mpl promoter is, however, downregulated in lineage restricted progenitor
cells other than the megakaryocytic progenitor cells 86 and therefore no further
amplification of blood cells different from the megakaryocytic lineage is likely
to be supported by the mpl-TG. This would explain why the numbers of
circulating blood cells in mpl knockout mice expressing the mpl-TG are in the
normal range (Table 2).
mpl locus
+ / + + / ko ko / ko
TG
n
HGB
g / dl
WBC
x(106/ml)
platelets
x(106/ml) n
HGB
g / dl
WBC
x(106/ml)
platelets
x(106/ml n
HGB
g / dl
WBC
x(106/ml)
platelets
x(106/ml)
non
e
12 14.1
± 0.1
14.3 ±
0.7
1‘180 ±
50
5 12.3 ±
0.5
  7.4 ±
0.8
1‘665 ±
40
5 14.2
± 0.9
  6.7 ±
1.7
   208 ±
30
mpl 10 14.5
± 0.2
13.1 ±
2.1
1‘390 ±
70
5 14.5 ±
0.7
10.9 ±
0.5
1944 ±
100
5 12.9
± 0.4
  9.5 ±
0.8
5‘248 ±
320
Table 2. Blood was obtained from non-transgenic and transgenic mice by cardiac puncture and
analyzed as described in Materials and Methods. Shown are the concentrations of hemoglobin
(HGB), and the numbers of white blood cells (WBC) and platelets. The mice were either
homozygous for the endogenous mpl allele (+/+), or heterozygous (ko/+) or homozgous (ko/ko)
for the mpl knockout allele.
Histopathology of mpl-TG mice. Morphologically and functionally, platelets
and megakaryocytes in transgenic mice are normal. We could not observe
changes in platelet activation or in megakaryocyte ploidy, a measure for the
maturation stage of megakaryocytes (data not shown). Histopathological
analysis of transgenic mice, however, revealed not only an increase of
megakaryocytes in bone marrow but in spleen (Fig. 3). Furthermore, the
spleen sections contained aggregates of small particles (Fig. 3). To identify
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the nature of these particles, electron microscopic analysis of spleen sections
was performed. In mice carrying the mpl-TG but not in wild type controls, we
detected areas containing densely packed platelets, as identified by size,
morphology, and the presence of usually one identifiable dense granule per
platelet 139 (Fig. 4).  Moreover, the spleens in mpl-TG animals are enlarged
(data not shown), which can be explained by the congestion of the spleen with
platelets and the increase in megakaryopoiesis.
Fig. 3 Platelet-like particles are found in the spleen of transgenic mice.
Representative sections show an increase in the number of megakaryocytes (big
arrow) in spleen of transgenic (ko/ko TG-mpl) compared to wild type mice (wt). The
small arrow points at aggregates of small platelet-like particles, which are only found
in transgenic mice.
TPO levels in circulation and c-mpl expression on platelets. In
experimental murine models, it has been shown that TPO over-expression
causes thrombocythosis in vivo 147,148. Further, mutations in the TPO gene,
which result in elevated TPO plasma levels, are the underlying cause of one
form of hereditary thrombocythemia in humans 149,150. We therefore tested
whether TPO levels in circulation were altered in mice expressing the mpl-TG.
We found that this was not the case (Fig. 5A). Therefore, higher levels of
circulating TPO do not cause the observed thrombocytosis. Contrarily, it
would have been expected that thrombocythemic mice have reduced TPO
plasma levels due to increased platelet numbers, because platelets have
been shown to play a key role in plasma clearance of TPO 84. It has been
demonstrated that platelets actively bind TPO via mpl, and internalize and
Results I 54
degrade the protein 151,152. This situation, where thrombocytosis is
accompanied by normal TPO levels, resembles human ET. In patients with
ET, for reasons not yet understood, expression of c-mpl protein is dramatically
reduced in platelets, which may account for the normal or slightly elevated
TPO levels in circulation 153. We therefore tested mpl-TG protein expression
on platelets (Fig 5B). Despite the equal expression levels on megakaryocytes,
mpl-TG protein expression is reduced on platelets. The expression of mpl-TG
mRNA levels is, however, similar to endogenous mpl mRNA in non-transgenic
wild type controls (data not shown). This indicates that the transgenic protein
is less stable or less efficiently translated. Factor independent growth of
megakaryocytic progenitors as a second possible explanations for the
observed thrombocytosis could also be ruled, because CFU-Meg cultures of
bone marrow cells derived from transgenic aimals are TPO-dependent (data
not shown).
mpl locus TG n total
number of
cells/ femur
(x 106 )
CFU-G
per 5 x 104
cells
CFU-GM
per 5 x 104
cells
CFU-M
per 5 x 104
cells
BFU-E
per 5 x 104
cells
+ / + none 3 26.7 ± 4.5 4.3 ± 0.7 3.3 ± 0.9 56 ± 5.8 5.3 ± 1.6
ko / ko none 3 31.1 ± 3.2 2.5 ± 0.8 1.5 ± 0.3 52 ± 3.4 3.5 ± 0.8
ko / ko mpl 3 18.5 ± 1.4 12.0 ± 3.1 6.0 ± 1.2 147 ± 20.6 9.7 ± 3.2
Table 3. Bone marrow cells form different mouse strains were cultured as described
under Materials and Methods. Colony forming units (CFUs) for neutrophil (G),
neutrophil-macrophage (GM), and macrophage (M)  as well as burst forming units for
erythrocytes (E) were scored. Bone marrow cells from three mice were analyzed for
each genotype.
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Endogenous mpl locus restores platelet count to wild type levels. Mice
expressing full-length mpl as a transgene in a mpl knockout background lack
all alternate mpl isoforms. To address the question whether the observed
thrombocythemia is caused by the absence of alternative mpl isoforms, we
reintroduced the endogenous mpl locus into the thrombocythemic mice, which
are homozygous for the mpl knckout allele. The resulting transgenic mice,
which are heterozygous for the endogenous locus, show platelet numbers
similar to their non-transgenic littermates (Fig. 6A). Along the same lines, no
difference exists between the number of megakaryocytic precursors of
transgenic and non-transgenic ko/+ mice, as assessed by CFU-Meg assays
(Fig. 6B). These results suggest that the endogenous mpl locus exerts a
dominant-negative effect over the mpl-TG.
Fig. 4 Electronmicrographs of
spleen. Spleen tissues of wild type
and transgenic knockout mice were
processed for electron microscopy.
In transgenic but not in wild type
spleen, areas with densely packed
platelets were identified. The large
arrow indicates the boundaries of
platelets. The small arrow points at
a dense granule within a platelet.
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Lack of mpl-tr is not sufficient to cause thrombocythosis. Two murine
alternate mpl isoforms have been identified: mpl-tr 74 and mpl-II 80. We have
recently characterized one of these variants, mpl-tr, as a dominant-negative
regulator of mpl function (Coers et al, in press). One possible way to explain
the observed thrombocythemic phenotype is the absence of mpl-tr. To test
this hypothesis, we took advantage of the existence of the mpl allele, D60.
This allele was generated using the knock-in approach to replace exons 11
and 12 encoding the intracellular region of c-mpl with a cDNA fragment
encoding only the first half of the cytoplasmic signaling domain 154 (Fig. 7A).
Fig. 5 TPO serum levels are
normal in transgenic mice. (A)
Serum TPO levels were determined
as described in Materials and
Methods. Because platelets
sequester and thereby diminish the
concentration of TPO through
binding of TPO to mpl protein,
TPO serum levels are elevated in
mpl knockout mice. However,
transgenic mice, albeit having five
times higher platelet numbers
compared to wild type mice, show
TPO levels that are similar to wild
type mice. (B) Immunoblotting for
mpl  prote in  shows that
thromobocythemic transgenic mice
(ko/ko TG-mpl) express mpl
protein at much lower levels than
wild type mice (wt).
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Fig. 6 Endogenous mpl locus reverts thrombocythemic phenotype in transgenic
mice. (A) The platelet counts of non-transgenic (white boxes) and transgenic (black
boxes) mice in the absence (ko/ko) and presence (ko/+) of the endogenous mpl locus
are shown. Platelet counts were determined of at least 5 mice for each genotype. (B)
The same mice were analyzed for the number of megakaryocytic precursors in the
bone marrow, as determined in CFU-Meg assays, as described in Materials and
Methods.
Mice homozygous for D60 have, by and large, normal platelet counts, showing
that the last 60 C-terminal amino acids of mpl are not essential for normal mpl
function in vivo 154. Because the splice acceptor for the generation of mpl-tr is
removed in the D60 allele, mpl-tr is expected to be absent in mice
homozygous for D60 (Fig 7A). Using 3’ RACE, we could confirm lack of mpl-tr
(data not shown). We also confirmed the expression of the mpl-II variant in
D60 homozygous mice (data not shown).  Next, transgenic ko/ko mice were
backcrossed with mice homozygous for D60 to obtain transgenic and non-
transgenic mice with a ko/D60 mpl genotype. Like the wild type mpl alelle, the
D60 allele reduced platelet counts of mpl-TG animals by about 70 % (Fig. 7B),
demonstrating that a dominant-negative mpl isoform different from mpl-tr must
exist.
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Fig. 7 Absence of mpl-tr does not cause thrombocythemia. (A) Schemata of the 3’
region of the mpl locus: the boxes represent exons. A line connecting exon 8 with
exon 7 indicates the splicing event generating the dominant negative variant mpl-tr. In
the D60 allele, exons 10 and 11 are removed. As consequence, mpl-tr is not generated
from this allele. (B) Platelet numbers are shown of non-transgenic (white boxes) and
transgenic (black boxes) mice expressing different combinations of mpl alleles, as
indicated. As shown, platelet numbers are five times the wild type counts in the
absence of the endogenous mpl (ko/ko). When the wild type allele (ko/+) or the D60
(ko/D60) allele is backcrossed into these mice, platelet numbers decrease by about
70% to numbers similar to platelet counts in wild type mice (+/+).
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Discussion
The precise mechanism by which hematopoietic progenitor cells proliferate,
mature and enter blood circulation is not known. Cytokines can stimulate cell
proliferation 93-95 or instruct cell fate determination 91,92. The cytokine
thrombopoietin and its receptor c-mpl are the principal regulators of
megakaryopoiesis 74,155-157. Mice deficient in TPO or its receptor continue to
produce functional platelets, albeit at much lower levels 82,83,131, suggesting
that c-mpl mainly controls quantitative aspects of megakaryopoiesis.
Consistently, studies done in knock-in animals, where the intracellular
domains of c-mpl and G-CSF-R have been interchanged, also indicate that
TPO supports thrombopoiesis primarily by promoting proliferation of
megakaryocytic progenitors 94. Because hyperproliferation of the
megakaryocytic lineage is often observed in
myeloproliferative disease, it is of particular interest to understand how the
TPO signal is attenuated. One negative regulator of megakaryopoiesis is
transfoming growth factor-beta 158, which reduces TPO-induced STAT5 and
ERK1/ERK2 activity 159. Additionally, interferon-alpha directly inhibits TPO
induced cell growth, possibly by inducing SOCS-1 expression and inhibiting
JAK2 160. However, the in vivo importance of these hormone in regulating
thrombopoiesis in largely undetermined.
Alternatively spliced cytokine receptor variants have emerged as important
regulators of cytokine signaling 36-38. Recently, we have characterized the
alternate mpl isoform mpl-tr as a dominant-negative regulator of TPO
dependent proliferation and survival signaling. To test for the importance of
alternate mpl isoform in vivo, we generated transgenic mice, which express
only the full-length mpl isoform. Interestingly, these mice show an expansion
of the number of megakaryocytic progenitors and have five times elevated
platelet counts. We have found that the reintroduction of the endogenous mpl
allele restored platelet counts to normal, demonstrating that the mpl allele
contains a dominant-negative regulator of thrombopoiesis.
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Two different mpl knockout alleles exist.  Alexander et al. generated a
genuine mpl knockout allele, removing a 2.6 kb fragment was removed
bearing exons 1 to 5 and the core mpl promoter 83. Expression of the mpl TG
in mice homozygous for this mpl null allele causes severe thrombocythosis
(Kaushansky, personel communication), in agreement with our observation.
The knockout allele used in this study has a neo-cassette inserted in mpl exon
3 82. It is unlikely that the chromatin organisation in the vicinity of the mpl gene
is drastically altered by either the neo-cassette insertion or by the deletion of
five mpl exons.  However, both knockout alleles lack components that restrict
the expansion of the megakaryocytic lineage. Therefore, the inhibitory
regulator of thrombopoiesis must be expressed by the endogenous mpl locus.
We propose that dominant-negative mpl isoforms constitute this inhibitory
effect on megakaryopoiesis. In this study, we used the mpl knock-in allele
D60, which does not give rise to the mpl-tr isoform (Fig. 7A). We show that the
D60 allele, like the endogenous mpl allele, contains an element inhibiting
megakaryocytic proliferation. This result suggests that an additional dominant-
negative mpl isoform other than mpl-tr must exist. An alternative splice
Fig. 8 The three known mouse mpl
isoforms are shown in a schematic
drawing. The full-length mpl receptor
consists of two cytokine receptor homology
modules (CRH) in the extracellular portion,
a transmembrane domain and an
intracellular signaling domain. An
alternative splice acceptor site in exon 4
generates the isoform mpl-II with an in-
frame deletion of 60 amino acids between
the two conserved cysteine pairs in the
distal CRH. The deleted region is probably
important in ligand binding. The third
isoform, mpl-tr, is due to alternative
splicing of exon 8 directly to exon 11,
eliminating the juxtamembrane WSXWS
motif, the transmembrane domain, and the
intracellular domain. Due to a frame-shift
at the splicing site, the C-terminus of mpl-
tr consists of a peptide of unique sequence,
30 amino acids in length. This peptide is
required for the anti-proliferative response
mediated by mpl-tr.
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acceptor site in exon 4 generates the isoform mpl-II, which is expressed by
both the endogenous mpl and the D60 knock-in allele (Fig. 7A). The mpl-II
isoform has an in-frame deletion of 60 amino acids between the two
conserved cysteine pairs in the distal cytokine receptor homology domain
(CRH) of mpl (Fig. 8) 80. This region constitutes the dimer interface homology
region 161. It has been shown that the distal CRH is required for TPO binding
but not for receptor dimerization and signaling 162. The importance of the
deleted portion of mpl in receptor activation is supported by the finding that
the introduction of cytosine residues in this region renders mpl constitutively
active 161. We propose that this recently described isoform acts as a
dominant-negative by binding to full-length mpl, thus forming a heterodimer,
which fails to bind ligand. This concept will require experimental proof in the
future.
Interestingly, the increased platelet levels in the thrombocythemic mice are
accompanied by decreased mpl protein expression on platelets. It has been
hypothesized that TPO levels in circulation are mainly controlled by platelet
84,163-165 mass through c-mpl mediated uptake and metabolism. According to
this model the highly elevated platelet levels would lead to TPO plasma levels
below the detection limit of the ELISA. However, TPO levels in the
thrombocythemic mice were normal. It is therefore not only the platelet and
megakaryocyte mass but also the c-mpl expression level on platelets that
regulates the TPO serum concentration. It is to date not clear, why the
transgenic protein is less stable in platelets, especially because expression
levels in megakaryocytes are normal. The combination of a thrombocytosis
accompanied with normal TPO levels in circulation and reduced c-mpl
expression on platelets has been observed in 17 out of 17 patients with ET 153
and less frequently in sporadic cases of polycythemia vera and chronic
idiopathic myelofibrosis 1. With our mpl knockout mice expressing mpl-TG we
have an animal model at hand that allows us to study the basis of the
decreased c-mpl expression on platelets and which may also allow the testing
of future ET therapies.
Results II 62
RESULTS II:
Cloning of a GATA-1 regulated gene encoding a novel
SIAH-interacting protein
Jörn Coers, Nico Ghilardi and Radek C. Skoda*
Department of Research, Experimental Hematology, Basel University Hospitals, Hebelstrasse
20, 4031 Basel, Switzerland.
Running title: Identification of a novel GATA-1 regulated gene
Key words: GATA-1, SIAH, GASIP, thrombopoietin, platelets
Results II 63
Abstract
A few common hematopoietic progenitor cells produce many vastly different
cell types. The diversification of cell types is controlled through the use of both
lineage-restricted and more widely expressed transcriptional regulators and
the combinatorial actions of these regulators specify gene expression. The
differentiation of megakaryocyte precursors is dependent on the proper
function of the GATA-1 transcription factor. Mice lacking GATA-1 selectively in
megakaryocytes have dramatically fewer platelets but more megakaryocytes,
altered platelet size and shape and prolonged bleeding times. Further, GATA-
1-null megakaryocytes hyperproliferate in vitro, suggesting that GATA-1 is
both a differentiation factor and negative regulator of megakaryocyte cell
proliferation. However, GATA-1 regulated genes which are responsible for this
growth inhibition are presently unknown. The cytokine thrombopoietin and its
cognate receptor c-mpl are the main stimulators of megakaryocyte
proliferation. In this study we have identified a novel gene, GASIP, which is
dramatically downregulated in mpl-transfected hematopoietic cell lines,
identifying mpl as a negative regulator of GASIP expression. The presence of
juxtaposed GATA and Ets-binding cis-elements in the GASIP promoter are
typical for a megakaryocytic gene. Indeed GASIP expression in platelets is
robust and correlates with mRNA levels of GATA-1, but not GATA-2 or –3,
identifying GATA-1 as a positive regulator of GASIP expression. The finding
that mpl and GATA have opposite effects on both proliferation and on GASIP
expression, make GASIP a candidate GATA-1 target gene involved in growth
inhibition. To investigate the potential role of GASIP in growth regulation, we
screened for potential protein binding partners. Interestingly, we identified the
p53-inducible tumor suppressor seven in absentia homologe (SIAH) as a
GASIP interacting protein. We speculate that GASIP may contribute to the
anti-proliferative effect of SIAH.
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Introduction
The hematopoietic system consists of eight distinct cell lineages that are
derived from a common precursor in an ongoing process that involves the
selective activation of gene expression programs characteristic of individual
cell types. Several transcriptional regulators are involved in hematopoietic
gene regulation. Phenotypes of c-Myb-, AML-1-, GATA-2- and SCL-1-
deficient mice reveal a profound failure of definite hematopoiesis 166-170. In
contrast, GATA-1, PU.1, E2A, C/EBPa,  C/EBPb,  and C/EBPe knockouts
have more selective phenotypes 171-179. One theme to emerge from gene
targeting experiments and complementary studies in cell differentiation in vitro
is that cell-restricted expression of lineage specific genes is achieved through
the use of both lineage restricted and more widely expressed transcriptional
regulators. Several advances have highlighted the particular importance of the
erythro-megakaryocytic transcriptional regulator of the GATA family of zinc-
finger proteins, GATA-1, in megakaryocyte and platelet differentiation.
The rat platelet factor 4 and human glycoprotein IIB genes are regulated in
part through isolated GATA sites or the combination of juxtaposed GATA and
Ets-binding cis-elements 180,181. Additionally, virtually every examined gene
with elevated expression in megakaryocytes reveals functional GATA and Ets
cis-elements 182,183. This holds true for the c-mpl gene, which encodes the
thrombopoietin receptor, the most important regulator of platelet homeostasis
74,82,155-157. To a large extent, c-mpl expression in megakaryocytes is regulated
by GATA- and Ets-family transcription factors 78,184. Mice lacking GATA-1
selectively in megakaryocytes 185 and humans with critical GATA-1 point
mutations 186,187 have defects that reveal many of the requirements for this
factor in thrombopoiesis. Absent or impaired GATA-1 function is associated
with thrombocytopenia and defective platelets as a result of a unique
megakaryocyte differentiation arrest 185-188. These and other findings indicate
that GATA-1 must regulate a portion of the program of gene expression that
regulates cell replication, drives cytoplasmic maturation in megakaryocytes,
and coordinates the development of platelet organelles. Other features,
including proplatelet formation and regulation of platelet size and numbers,
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may either be directly under GATA-1 control or simply reflect the failure of the
cells to progress beyond an early differentiation block.
The cytokine thrombopoietin and its cognate receptor c-mpl are the key
regulators of the quantitative aspects of thrombopoiesis. Accumulating
evidence also points to an important function of mpl in hematopietic stem cell
(HSC) self-renewal and expansion 85. It has recently been shown that TPO
regulates the expression of the homeobox transcription factor Hoxb4 189,
which has been demonstrated to function in regulating the HSC pool 190-193.
The goal of our study was to identify other genes which are transcriptionally
regulated by mpl. We cloned a gene that is downregulated in hematopietic cell
lines when mpl is expressed. The expression of this gene, which has been
named GASIP for GATA-1 regulated SIAH Interacting Protein, appears to be
under the transcriptional control of GATA-1 in vivo. Contrarily to mpl, GATA-1
is negative regulator of megakaryocyte cell proliferation. The finding that mpl
and GATA have opposite effects on both proliferation and on GASIP
expression, make GASIP a candidate GATA-1 target gene involved in growth
inhibition To gain insights into the potential function of GASIP protein, we
performed Yeast-Two-Hybrid screens. Notably, we identified the tumor
suppressor SIAH as a binding partner of GASIP protein and we speculate that
GASIP may contribute to the anti-proliferative effect of SIAH. Additionally, we
identified cytoskeletal proteins, the RNA binding protein hnRBP E1 and the E3
ubiquitin ligase and tumor supressor SIAH as GASIP interacting proteins. The
interactions of GASIP with filamin, actinin and a kinesin suggest a potential
function of GASIP in cytoskeletal rearrangements.
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Materials and Methods
Cloning of murine and human GASIP cDNA
The fragment obtained by differential display was used to screen a mouse cDNA library. 5
independent clones were obtained and sequenced. A genomic clone was isolated from a
bacterial artificial chromosome (BAC) library (Genome systems, St. Louis). The clone address
is 212: A20. The murine GASIP sequence was used to search the cDNA clone database at
the Deutsches Ressourcenzentrum für Genomforschung (www.rzpd.de) and several clones
were obtained. The IMAGp998E0411679 clone was found to have an insert encoding the
entire hGASIP cDNA.
Expression analyses
Blood samples were processed as described elsewhere 1. Northern blot analysis was
performed as described by standard textbooks. The probe was amplified from the sequence
fragment out of the DD-RT-PCR screen using TCAGCAAAAACACACCATAC (sense) and
ATTCGTTTCCAGAAGCATTG (antisense). For quantitative polymerase chain reaction (Q-
PCR) RNA was extracted from cell lines by means of Trizol reagent (Life technologies,
Rockville, MD). RNA was treated with RNase-free Dnase (Promega, Madison, WI) for 90
minutes at 37°C, heat-inactivated and then purified with RNAeasy (Qiagen, Germany)
according to manufactures protocol. For reverse-transcriptase-polymerase chain reaction
(RT-PCR), 1mg of RNA was reverse-transcribed after random hexamer priming in a 30-mL
reaction mix containing 100 U of omniscript RT (Qiagen, Germany). Differential quantification
was performed on an ABI Prism 7700 sequence detector (Applied Biosystems, Foster City,
CA), as described 1.  The following primers were used for SYBR-PCR: mGASIP:
GATCATGGCTCGTCTGCAAGA (sense), GACACTGATGCTGACGTGGAA (antisense);
hGASIP: GACCAATGGAGATAAGCTCCGA (sense), GGCACCCGGGCTAGGTTA
(antisense); human MPL: AGCCCTGAGCCCGCC (sense),
TCCACTTCTTCACAGGTATCTGAGA (antisense); GATA-1: GCCCAAGAAGCGCCTGAT
(sense), TGGTCGTCTGGCAGTTGGT (antisense); GATA-2:
CCTCTACTACAAGCTGCACAATGTTAA (sense), CCGAGTCTGGATCCCTTCCT
(antisense); GATA-3: GGCTCTACTACAAGCTTCACAATATTAACA (sense),
TTGCTAGACATTTTTCGGTTTCTG (antisense). To prevent influence from genomic DNA
amplification, all primers were designed across exon-intron junctions. The GASIP primers
were designed to detect both of two putative splice variants. The DCT values were derived by
subtracting the threshold cycle (CT) values for GASIP, MPL and GATA-1 to -3 from the CT
value for mouse or human ribosomal protein L19 (RPL19), which serves as an internal control
1,108. All reactions were run in duplicates.
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Sequence analyses
Primers specific for the mGASIP cDNA were used to identify the location of introns. Using
long range PCR, the sizes of the introns were determined except for intron 2. The size of
intron 2 was determined by sequencing portions of the mGASIP genomic BAC clone and
constructing a contig. For the alignment of the sequences “Sequencer" software (Gene Codes
Inc., Ann Arbor, MI) was used.. Exons of hGASIP were identified by a Blast 194 search with
the human GASIP cDNA sequence in the human genome database at the NCBI
(http://www.ncbi.nlm.nih.gov/genome/seq/HsBlast.html). Intron sizes given by the AceView
analysis (http://www.ncbi.nlm.nih.gov/AceView/) were compared with the numbers obtained
by a Blast search of Celera's assembled sequence of the human genome
(http://public.celera.com). Sequences of the putative promoter regions of GASIP were
obtained by sequencing of the mGASIP genomic BAC clone and by identifying the region
upstream of the first hGASIP exon in the human genome database. Potential binding site of
transcriptional regulator were identified using the softwares TFSEARCH 195 and TESS
(http://www.cbil.upenn.edu/tess).
Analyses of GASIP protein interactions
A human bone marrow cDNA library was screened with the indicated portions of GASIP as a
bait using the Matchmaker system III (Clontech), following the manufacturer's instructions.
Transformants were obtained under high stringency conditions using growth media lacking
Ade/His/Leu/Trp. The specificity of the interaction was confirmed using a b-galactosidase-
DNA binding domain hybrid (G4-DB-hybrid) of the laminin protein as bait and two b-
galactosidase activation domain hybrids as prey for negative controls. Selected clones were
individually streaked out onto new plates and prey plasmids were isolated, amplified in E. coli
and retransformed into yeast strains. The original interaction was reconfirmed by natural
mating, followed by growth on selective media as well as screening for b-galactosidase
activity, as described in the manufacturer’s manual. HA-tagged GASIP and myc-tagged
SIAH-2 were 196 methionine labeled by transcription and translation using the TNT kit
(Promega Corp., Madison, WI). After synthesis, the lysate was diluted with 87.5 µl incubation
buffer (10% glycerol, 100 mM KCl, 20 µM Tris/HCl, pH 7.9, 0.5% NP40, and 1% BSA without
EDTA and dithiothreitol). The reactions were incubated with anti-myc, anti-HA antibodies or
no antibodies, respectively, at 4°C O/N and then 20ml of protein A/G agarose beads
(Promega Corp., Madison, WI) were added. After one hour of incubation, the beads were
washed three times with the incubation buffer. SDS-PAGE lysate buffer was added and the
reaction was bioled for minutes. The protein complexes were analyzed by electrophoresis
through a 10% polyacrylamide gel containing. Gels were dried and exposed to film.
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Results
Cloning of mouse GASIP (GATA-1 regulated SIAH Interacting Protein).
To identify mpl-regulated genes, we generated stable transfections of the
murine IL-3-dependent BaF3 cell line with cDNAs encoding murine c-mpl or,
as a control, human IL-4R. Cell clones were cultured in the presence of TPO
or either IL-4 or IL-3, and mRNA expression of cells grown in the presence of
these different cytokines was compared by the differential display method.
The screen yielded four differentially regulated sequence fragments after
confirmation by Northern blot analysis (data not shown). One of the four
sequences corresponds to the mast cell carboxypeptidase A gene, which has
previously been shown to be differentially regulated by individual cytokines
196,197. Of the three remaining sequences, two are regulated by IL-4R signals
and only one is specifically regulated by c-mpl. The sequence of this fragment
shares 100% homology with the cDNA clone MGC:32254 (accession number
BC025223). Next, by screening a mouse cDNA library, cDNA clones were
obtained. The gene product encoded by these cDNA clones will be referred to
as GASIP (GATA-1 regulated SIAH Interacting Protein) from now on. A
genomic clone was isolated from a BAC library. Sequence analysis of the
murine genomic GASIP clone identified seven exons spanning  ~ 54 kb of
mouse genomic DNA, the size of the individual introns and the genomic
sequence surrounding the transcriptional start site (Fig. 1). The mouse GASIP
(mGASIP) cDNA is identical the transcript represented by the TIGR
consensus sequence TC255155, which is localized to the piebald deletion
region of mouse chromosome 14 198.
Downregulation of GASIP in mpl transfected hematopoietic cell lines.
Next, we confirmed the c-mpl mediated downregulation of GASIP by Q-PCR.
The expression of GASIP is reduced by more than 10 DCT values, which is
equivalent to a 210 fold reduction in GASIP mRNA expression, in BaF3 cells
expressing either murine or human TPO-R (Fig. 2A). Interestingly, five c-mpl
expressing BaF3 clones downregulated GASIP in the absence of TPO and
three cell clones
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required TPO for a transient reduction in GASIP mRNA (data not shown).  To
examine whether downregulation of GASIP mRNA following ectopic
expression of a cytokine receptor is specific to mpl, we assessed GASIP
expression in a number of clones transfected with cDNAs encoding mGCSF-
R, mIL-4R, mOB-R or mEPO-R, respectively. Downregulation of GASIP was
not found in any of these cell lines (Fig. 2A and data not shown). Interestingly,
a chimeric receptor consisting of the intracellular portion of mpl and the
extracellular domain of GCSF-R triggered a reduction in GASIP expression.
This is in contrast to a second chimeric receptor with the intracellular domain
of GCSF-R and the extracellular portion of mpl, which did not affect GASIP
expression (Fig. 2A), suggesting that the downregulation of GASIP is
dependent on the intracellular domain of mpl. We were further able to observe
ligand independent downregulation of GASIP mRNA following ectopic
expression of TPO-R in FDCP-1 cells, a second IL-3 dependent cell line (Fig.
2B), thus excluding mpl-dependent GASIP regulation as a BaF3 specific
phenomenon. In the human cell line UT7/TPO, which expresses endogenous
mpl and which is responsive to TPO, stimulation with TPO triggers only a
moderate and transient reduction in GASIP mRNA expression by two to three
fold (data not shown).
Sequence analysis of GASIP protein. We decided to study GASIP in more
detail for two reasons. First, the reduction in GASIP expression in the
presence of mpl might indicate that GASIP is inhibitory to the proliferation or
differentiation of megakaryocytes, and secondly, the unusual mode of
regulation suggests an alternative ligand-independent mechanism of mpl
function. The cDNA of
Fig. 1. (opposite page) Composite genomic and cDNA sequence for mouse
GASIP.  The sequence shown is composed of genomic sequence (position – 600 to
+554) and of cDNA sequence (position –128 to +2734; the polyA-tail is not shown).
The sequence of the overlapping region from –128 to +554 is identical. Potential
binding sites for transcription factors surrounding the transcription initiator site (Inr)
are indicated. Important restriction sites are included in this diagram. The positions of
introns are indicated by open triangles and the intron sizes in kb are stated above the
triangles. The amino acid sequence for the identified longest ORF is shown. Indicated
are amino acid sequence stretches for putative coiled coil and PEST domains.
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mGASIP is 2862 nucleotides long (Fig. 1), which is in the same size range as
the 2.9 kb mRNA detected by Northern blot analysis (data not shown). The
longest ORF encodes a protein of 579 amino acids with a calculated
molecular weight of 61 kDa.  It is characterized by a high proportion of serine
and threonine residues (20%) and proline residues (12%). The N-terminus
contains a stretch of 30 amino acids, which are predicted to form a coiled coil.
The central region of the protein has a predicted PEST domain (Fig. 1).
However, in spite of three proline rich clusters, GASIP shows no particular
domain or sequence motif or homology to any characterized protein.
Fig. 2. Expression of mGASIP in BaF3 and in FDCP-1 cells transfected with the
indicated cDNAs. (A) BaF3 cell clones transfected with mouse (mpl-1 and –2) and
human (Mpl-1 and –2) TPO-R  and control constructs are shown. Expression levels of
GASIP are in given as DCT values. High DCT values indicate low expression. For
instance, the GASIP (DCT) value in parental BaF3 cells is about 8, but in mpl-
transfected BaF3 cells the GASIP (DCT) value goes up to 18. This equals a decrase in
GASIP expression by 210 fold in mpl expressing cells. (B) Shown are the GASIP
(DCT) values in parental FDCP-1 cells and in mpl transfected FDCP-1 cells.
Human and mouse GASIP are highly conserved. The human ortholog was
cloned as described in Materials and Methods. The human GASIP (hGASIP)
cDNA is 3146 nucleotides long (Fig. 3) and its longest ORF encodes a
protein, which is 641 amino acids in length.  Human and murine GASIP are
highly
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conserved with over 80% identity on protein level (data not shown). Genomic
sequence of hGASIP, which encompasses ~ 65 kb and maps to chromosome
13q22.3, was obtained by searching the public database of the human
genome.
Fig. 4. Intron/ exon structure of mouse and human GASIP. The additional exon,
found in the cDNA of human GASIP is termed 2b. The GASIP loci map to the
piebald deletion region of mouse chromosome 14 and the orthologous region of
human chromosome 13. The length of mouse and human GASIP introns in kb is
shown.
The intron/ exon structure of hGASIP is very similar to its murine ortholog
(Fig. 3) with the exception of one additional exon which we termed exon 2b
(Fig. 4). This is probably due to alternative splicing, because the exon 2b is
also found in the murine genomic GASIP locus and a mouse EST clone
(GenBank Acc: BE656090) containing this sequence exists. Searches in the
human and mouse EST databases did not identify any GASIP cDNAs
extending at the 5’ end of the sequence shown here, suggesting that we have
obtained the complete human and mouse GASIP cDNAs.
GASIP and GATA-1 expressions correlate. Next, we investigated the effect
of human MPL on GASIP expression in vivo. We determined GASIP
expression in platelets obtained from healthy human individuals. Here,
expression levels of GASIP mRNA correlated positively with the amount of
MPL mRNA: individuals
Fig. 3 (Opposite page). Composite genomic and cDNA sequence for human
GASIP.  The sequence shown is composed of genomic sequence (position – 600 to
+629) and of cDNA sequence (position –207 to +2932; the polyA-tail is not shown).
The sequence of the overlapping region from –207 to +629 is identical. Potential
binding sites for transcription factors surrounding the transcription initiator site (Inr)
are indicated. Important restriction sites are included in this diagram. The positions of
introns are indicated by open triangles and the intron sizes in kb are stated above the
triangles. The amino acid sequence for the identified longest ORF is shown. Indicated
are amino acid sequence stretches for putative coiled coil and PEST domains.
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Fig. 5 Correlation of GASIP and GATA-1 mRNA expression. (A) Expression of
hGASIP and MPL mRNA positively correlate in platelets. Expression levels are
shown as DCT values. High DCT values indicate low expression. Each dot represents
the values of one healthy human individual. (B) Mpl expression is dependent on the
transcription factor GATA-1, which explains why GATA-1 and MPL mRNA levels
positively correlate in platelets. Expression levels are shown as DCT values and each
dot represents the values of one healthy human individual. (C) Similar to MPL
mRNA expression, the GASIP mRNA levels are higher the more GATA-1 is
expressed, suggesting transcriptional control by GATA-1. In contrast, GATA-2 and
GATA-3 expression levels show no significant correlation with the amount of GASIP
mRNA.
with high expression of MPL (low DCT value) also showed high expression of
GASIP and individuals with low expression of MPL (high DCT value) had
accordingly less GASIP mRNA (Fig. 5A). This result appeared to conflict with
our in vitro data. To clarify whether TPO-R protein expression has a positive
effect on GASIP expression in the megakaryocytic lineage in vivo, we looked
at GASIP and MPL expression in patients who suffer from sporadic
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myeloproliferative disease (MPD). We chose MPD patients, who have
drastically diminished MPL protein expression but normal MPL mRNA
expression in platelets 1. In these patients GASIP mRNA expression still
positively correlates with MPL mRNA levels (data not shown), suggesting that
MPL protein expression and thus signaling through TPO-R is not responsible
for the observed correlated expression of MPL and GASIP. An alternative
explanation for the observed linear relationship between GASIP and MPL
expression would suggest that GASIP could positively regulate MPL
transcription. However, overexpression of GASIP in UT7/TPO cells had no
effect on MPL expression (data not shown). We thus speculated that TPO-R
and GASIP are transcriptionally regulated in a similar fashion. Alignment of
the sequences surrounding the transcriptional start sites of both murine and
human GASIP allowed us to identify conserved putative binding motifs for
transcription factors. This analysis revealed a conserved CAAT box and
potential binding motifs for members of the GATA, Ets, and C/EBP families of
transcription factors amongst others (Fig. 2 and 3). Particularly, the
combination of juxtaposed GATA and Ets-binding cis elements found in the
GASIP promoter is characteristic of megakaryocytic genes like mpl. Indeed,
the expression of MPL mRNA correlates with the expression levels of GATA-1
in platelets of healthy individuals (Fig. 5B). Similarly, the mRNA expression of
GASIP correlates with the expression level of GATA-1, but not GATA-2 or –3
(Fig. 5C), suggesting GATA-1 to be a regulator of GASIP transcription. To
compare the expression of GASIP in different hematopoietic cell lineages, the
blood from healthy donors was fractionated into platelets, adherent and non-
adherent mononuclear cells and granulocytes. The lowest expression of
GASIP is found in macrophages and lymphoid cells, which make up most of
the non-adherent mononuclear cells (Fig. 6A). In platelets the average GASIP
(DCT) value is ~ 4 compared to ~7.5 in the lymphiod compartment and ~8.5 in
macrophages (Fig. 6A), which means that the expression of GASIP is about
10 - 20 times higher in platelets than in mononuclear cells. In granulocytes the
average GASIP (DCT) value is ~ 2, which translates into a GASIP expression
of about 50 to 100 times that found in mononuclear cells (Fig. 6A).
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GASIP interacts with seven in absentia homolog (SIAH). Finally, to gain a
better understanding of potential biological functions of GASIP, we screened a
human bone marrow expression library for protein-protein interaction with
GASIP in a Yeast-Two-Hybrid screen. One GASIP ‘bait’ construct for the N-
terminus and two ‘bait’ constructs for the C-terminus were used (Fig. 7). To
avoid false positives, the screen was performed with two independent
selection markers. Additionally, clones were screened for lacZ expression as
a third maker. The obtained ‘prey’ plasmids were isolated out of the yeast
strain, amplified in E. coli, and sequenced. The purified plasmids were then
re-transformed into yeast and tested for unspecific activation of a G4-DB-
laminin control ‘bait’ construct and interaction with different GASIP constructs
(Table 1). This approach allowed the identification of true positives and a
summary of the results of the Two-Hybrid screens is shown in Fig. 7 and
Table 1. We identified three different cytoskeleton-associated proteins,
filamin, actinin alpha, and the kinesin KIF4, the RNA binding proteins hnRNP
E1 and the E3 ubiquitin ligase SIAH-1 and -2. This is in agreement with the
finding that SIAH interacting proteins are able bind to both family members
due to the high degree of homology between SIAH-1 and –2.  To further verify
the interaction of GASIP with SIAH, tagged versions of both proteins were
transcribed and translated in vitro. Immunoprecipitation of GASIP precipitates
SIAH and GASIP is co-immunoprecipitated with SIAH (Fig. 8), confirming
GASIP as a SIAH interacting protein.
Fig. 6 GASIP expression in blood
lineages.  The blood from six
healthy individuals was separated
into granulocyets (GR), mononuclear
cells (MN) and platelets (Pl), as
described 1. Macrophages (MF )
were isolated form the mononuclear
cell fraction by allowing them to
adhere to tissue culture dishes for
two hours. RNA from the different
cell fraction was isolated and Q-PCR
was performed. Each dot represents
the DCT value of the indicated cell
type from one healthy human
individual.
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Fig. 7 Summary of the results obtained from the Yeast-Two-Hybrid screen.
Three ‘bait’ constructs were used consisting of a GAL4-DNA-binding domain (G4-
DB) fused to the indicated portions of GASIP protein. These constructs were screened
against a human bone marrow cDNA library expressed as GAL4-activation domain
(G4-AD) fusion proteins. When a protein-protein interaction occurs, the G4-AD
activates expression of reporter genes. In screens with the three different ‘baits’
proteins were identified as GASIP interacting proteins as listed.
Fig. 8 In vitro translated radioactively
labelled HA-tagged GASIP and myc-
tagged SIAH-2 fusion proteins were
tested for protein interaction. The two
fusion proteins were mixed in binding
buffer and immunoprecipitated (IP) with
either anti-myc or anti-HA antibodies.
Protein A/G agarose beads alone (beads)
did not result in any protein precipitation.
HA-GASIP and myc-SIAH-2 co-
immunoprecipitate in the presence of
either anti-HA or anti-myc antibody. The
amounts of in vitro-translated proteins
added to the binding reaction are shown
in the lanes marked ‘input.’
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G4-DB-hybrid
‘bait’
G4-AD-hybrid
‘prey’
Growth on LWHA-plates b-Gal staining
laminin SIAH-2 (146-324) - -
GASIP (262-579) SIAH-2 (146-324) + +++
laminin SIAH-2 (1-324) - -
GASIP (211-579) SIAH-2 (1-324) + +++
GASIP (211-346) SIAH-2 (1-324) - -
GASIP (262-579) SIAH-2 (1-324) + +++
GASIP (262-386) SIAH-2 (1-324) - -
GASIP (262-346) SIAH-2 (1-324) - -
GASIP (348-579) SIAH-2 (1-324) + +++
GASIP (384-579) SIAH-2 (1-324) + +++
laminin SIAH-1 (1-313) - -
GASIP (262-579) SIAH-1 (1-313) + +++
GASIP (211-579) SIAH-1 (1-313) + +++
GASIP (262-386) SIAH-1 (1-313) - -
GASIP (384-579) SIAH-1 (1-313) + +++
SIAH-2 (1-324) GAL4 - -
laminin GASIP (1-579) - -
SIAH-2 (1-324) GASIP (1-579) + ++
laminin actinin a-3 (1-901) - -
c13 (262-579) actinin a-3 (1-901) + ++
c13 (211-579) actinin a-3 (1-901) + +++
c13 (262-386) actinin a-3 (1-901) - -
c13 (262-346) actinin a-3 (1-901) - -
actinin a-3 (1-901) GAL4 + +++
laminin filamin (2174-2692) - -
GASIP (262-579) filamin (2174-2692) + ++
GASIP (211-579) filamin (2174-2692) + ++
GASIP (262-386) filamin (2174-2692) - -
GASIP (262-346) filamin (2174-2692) - -
GASIP (348-579) filamin (2174-2692) + ++
laminin KIF 4 (776-1232) - -
GASIP (262-579) KIF 4 (776-1232) + ++
GASIP (211-579) KIF 4 (776-1232) + ++
GASIP (211-346) KIF 4 (776-1232) - -
GASIP (262-386) KIF 4 (776-1232) - -
GASIP (262-386) KIF 4 (776-1232) - -
GASIP (262-346) KIF 4 (776-1232) - -
GASIP (348-579) KIF 4 (776-1232) - -
laminin hnRNP E1 (21-356) - -
GASIP (1-106) hnRNP E1 (21-356) + +++
laminin PP2A  (1-590) - -
GASIP (1-106) PP2A  (1-590) + ++
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Table 1. (Opposite page) A human bone marrow cDNA library was screened for
GASIP protein interactions. Selected clones were individually streaked out onto new
plates and prey plasmids were isolated, amplified in E. coli and retransformed into
yeast strains. The original interaction was reconfirmed by natural mating, followed by
growth on selective media lacking Ade/His/Leu/Trp (LWHA) as well as screening for
b-galactosidase (b-Gal) activity, as described in the manufacturer’s manual. Growth
on selective plates is indicated (+). Very high (+++), high (++) or no (-) b-Gal activity
was determined. The specificity of the interaction was confirmed using a b-
galactosidase-DNA binding domain hybrid (G4-DB-hybrid) of the laminin protein
(laminin) as bait and b-galactosidase activation domain hybrids (GAL4) as prey for
negative controls. Additional relevant mating tests are listed. The numbers in brackets
indicate the stretch of amino acid sequence that is encompassed by the specific
construct. The SIAH-1-, one of the SIAH-2- and the actinin-constructs encode full-
length proteins.
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Discussion
Mechanisms of thrombopoiesis are of considerable interest in hematology and
cell biology, in part because of the variety of human thrombocytopenia
syndromes and because megakaryocyte differentiation encompasses many
unusual attributes like polyploidy, a unique set of organelles and the regulated
fragmentation of the cytoplasm to generate platelets.
Genetic studies have recently provided rich insights into the molecular and
transcriptional regulation of megakaryocyte differentiation and
thrombopoiesis. Three transcription factors, GATA-1, FOG-1, and NF-E2, are
essential regulators of distinct stages in megakaryocyte differentiation,
extending from the birth of early committed progenitors to the final step of
platelet release.
Much of the attention in transcriptional regulation of megakaryocyte genes
has focused on the GATA family of zinc-finger proteins, which activate
transcription by engaging the DNA consensus sequence (A/T) GATA (A/G) in
the cis-regulatory elements of many lineage-restricted genes. Mice lacking
GATA-1 selectively in megakaryocytes 185 and critical GATA-1 point mutations
in human disease 186,187 cause defects that reveal at least some of the
requirements for this transcription factor in thrombopoiesis. First, platelet
counts are about 15% of the normal, platelet size is increased at least twofold,
platelet shape is spherical rather than discoid, and the bleeding time is
prolonged 185-188. Second, GATA-1-null megakaryocytes proliferate
excessively in vitro, and their substantial accumulation in vivo appears to
reflect primary growth dysregulation rather than a secondary response to
thrombocytopenia 185,188. This finding suggests that GATA-1 is a negative
regulator of cell proliferation in early megakaryocyte progenitors.
In this study we have identified a novel gene, GASIP, which is downregulated
in hematopoietic cell lines, which express the c-mpl. However, the expression
level of GASIP positively correlates with the expression level of MPL in
platelets of human individuals. The phenomenon can be explained by the
presence of juxtaposed GATA and Ets-transcription factor binding sites in
both the mpl and the GASIP promoters, suggesting that the two genes are
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transcriptionally regulated in a similar fashion in megakaryocytes. It is known
that GATA-1 binds to the mpl promoter and, in concert with FOG-1, activates
mpl transcription. Indeed, the expression levels of MPL positively correlates
with the expression of GATA-1 in platelets (Fig. 5) and the same is true for
GASIP expression (Fig. 5), indicating that GASIP is regulated by GATA-1.
Importantly, TPO-R stimulates the proliferation of megakaryocytic precursors,
but appears to be dispensable for most aspects of megakaryocytic
differentiation. In contrast, as described above, GATA-1 is a negative
regulator for the proliferation of early megakaryocytic precursors, though
GATA-1 regulated genes, which are responsible for this growth inhibition, are
presently unknown. Possibly, GASIP is one of these genes, explaining why
mpl transfected cell lines reduce GASIP expression. Using purified
megakaryocytes, future work will clarify whether the mpl-dependent GASIP
downregulation is TPO-dependent in vivo. We expect TPO to be required to
transiently downregulate GASIP in megakaryocytes and foresee that this
downregulation contributes to the proliferative signal that is mediated by TPO.
The mRNA amounts in platelets are probably representative of
megakaryocytic steady state mRNA levels. We think that the steady state
expression of both GASIP and mpl mRNA is controlled by GATA-1, which
would explain the positive correlation of GASIP and MPL expression in
platelets.
Interestingly, we have identified the p53 regulated tumor suppressor SIAH 199-
204 as a binding partner of GASIP protein. The biological significance of this
interaction awaits clarification. Interestingly, the pool of myeloid progenitor
cells is expanded in the recently described SIAH-2 knockout mouse 205.
Additional effects of GATA-1 malfunction include a vast increase in numbers
of tissue megakaryocytes revealing an abnormally small and immature
cytoplasm that harbors few platelet granules amid highly disorganized internal
membranes 185,188. Thus, absent or impaired GATA-1 results in a unique
megakaryocyte differentiation arrest. This shows that, in addition to
attenuating cell replication in precursors, GATA-1 also drives cytoplasmic
maturation in megakaryocytes and co-ordinates development of platelet
organelles. Other features, including proplatelet formation and regulation of
platelet size and numbers, may either be directly under GATA-1 control or
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simply reflect failure of the cells to progress beyond an early differentiation
block. Synthesis of platelet-specific organelles is mediated by a variety of
regulators of intracellular vesicle membrane fusion, and platelet release is co-
ordinated through extensive and dynamic reorganization of the actin and
microtubule cytoskeletons. The interactions of GASIP with actinin-a3, filamin
and the kinesin Kif 4A suggest a possible role of GASIP in this process.
Finally, we found the highest expression of GASIP in granulocytes. Notably,
forced GATA-1 expression induces the formation of eosinophil granulocytes in
hematopoietic progenitors from human cord blood 206 and GATA-1 is required
for the differentiation of eosinophils in vivo 206,207. Yu et al. describe a double
GATA binding motif as a regulatory element in the GATA-1 promoter that
selectively governs expression of GATA-1 in eosinophils 207. Interestingly, the
GASIP promoter also contains a double GATA motif  (Fig. 1 and Fig. 3). This
may explain the high expression of GASIP in granulocytes and suggests that
GASIP is an important GATA-1 target gene with a possible role in eosinophil
formation.
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PERSPECTIVES
Many aspects of cell behavior, such as growth, motility, differentiation, and
apoptosis, are regulated by signals which cells receive from their
environment. Such signals are critical during many physiological processes
like embryonal development, wound healing, hematopoiesis, and in the
regulation of the immune response. Extracellular stimuli such as hormones,
growth factors, and cytokines bind to and activate receptors at the cell
surface. However, signal transduction cascades are not simple one-way
streets. They are modulated at every step. Signals conveyed from receptors
are relayed, amplified, and integrated, resulting in the expression of target
genes in the nucleus and subsequent biological responses, which also
depend on the activity of other signaling events and/or the ‘history’ of a cell. In
the first part of my thesis, I studied the importance of alternate cytokine
receptor isoforms as regulators of signaling exemplified by the thrombopoietin
receptor. In a second project, I studied the role of mpl signaling in regulating
the expression of a novel gene with a potential function in cell differentiation
and proliferation.
Aberrations of cytokine signaling in disease
A number of pathological conditions have been identified with mutations in
cytokine receptors or associated signaling molecules. As could be expected
on the basis of the knockout models, mutations leading to a complete loss of
receptor function often give rise to severe disease phenotypes. Examples are
deleterious mutations in the leptin receptor, causing a syndrome
characterized by obesity and various forms of severe combined
immunodeficiency (SCID).
An important issue to be addressed is to what extent cytokine receptor
signaling contributes to tumorigenesis. Thus far, several reports link
aberrations in the JAK/STAT pathways to malignant phenotypes. In
mammals, JAKs and STATs are known to be constitutively activated in
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hemopoietic cells transformed by diverse oncogenic tyrosine kinases 208,209
and in a variety of lymphomas and leukemias 210-212. Expression of a
constitutively active STAT3 molecule in immortalized fibroblasts causes
cellular transformation 213. Further, JAK2 and STAT5B have been identified as
fusion partners in translocations in leukemias. In the Tel-JAK2 fusion protein
the kinase domain of JAK2 is constitutively activated leading to constitutive
activation of STAT proteins 214. STAT5B has been found to be fused to the
retinoic receptor alpha gene in patients with acute promyelocytic-like leukemia
215. Together these data are indicative of a role for constitutive activation of
the JAK-STAT pathways in leukemogenesis. It has been shown that
transforming mutations can also occur in cytokine receptors. Moreover,
several mutations in the EPO-R have been identified as the molecular lesion
resulting in human erythroid malignancies 216,217. Last but not least, the
thrombopoietin receptor was originally identified as a homolog of the viral
oncogene v-mpl 73, emphasizing the oncogenic potential cytokine receptors in
general.
Cytokine receptor splice forms and hematopoietic
malignancies
In my thesis work, I have charaterized the alternate mpl isoform mpl-tr as a
dominant-negative regulator of TPO signaling and provided circumstantial
evidence that a second alternative mpl variant, mpl-II, is an additional
dominant-negative isoform. Dominant-negative cytokine receptor isoforms
have also been identified for other cytokine receptors, but their importance in
vivo is not well defined, and most spliced isoforms have not been studied at
all. The importance of the mpl isoforms in regulating platelet counts suggests
a major regulatory function for alternate cytokine receptor isoforms in general.
Notably, many cancer-associated gene are regulated by alternative splicing
138. Although the functions of most spliced isoforms are not well defined, some
have antagonistic activities associated with cell death mechanisms. More
recently, it has become apparent that carcinogenesis induces changes in the
ratio of alternatively spliced isoforms that might affect cellular behavior and
tumorigenesis. Bcl-x, a member of the Bcl-2 family of apoptotic regulators,
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produces two alternatively spliced isoforms, Bcl-xL and Bcl-xS, with anti-
apoptotic and pro-apoptotic activities, respectively. The Bcl-xS protein is
upregulated in cells undergoing apoptosis and is downregulated in tumor
cells, whereas the Bcl-xL protein is predominantly expressed in many
lymphoma cells 218. Another example of the involvement of alternative splicing
regulation in cancer is the CD44 family of surface glycoproteins, which has a
role in cell adhesion and migration as well as in cell-matrix interactions. In
many human malignancies, certain CD44 splice variants predominate and in
the serum of gastric carcinoma patients, elevated levels of CD44v5 were
found to correlate with increased tumor invasion and metastasis 219.
Differences in the levels of alternatively spliced transcripts were suggested to
arise from differences in the mechanism regulating alternative splicing. The
possibility that changes in the regulation of alternative splicing might lead to
disease was studied in a mouse model for mammary gland tumorigenesis 220.
In this model, tumorigenesis was accompanied by changes in the relative
levels of CD44 transcripts, and a profound change in the repertoire and levels
of several splicing factors from the SR protein family. These results indicate
that changes in splicing regulation might have a significant role as a genetic
modifier of tumorigenesis. Interestingly, it has been shown that many alternate
cytokine receptor splice forms are differentially expressed during cell
differentiation and in cancerous cells 110,123,221-223, suggesting disruptions in
proper cytokine receptor splicing as a possible cause of hematopoietic
malignancies.
A mouse model of essential thrombocythemia
The mouse model analyzed in this work emphasizes the importance of splice
isoforms as inhibitory regulators in vivo, because the deletion of the dominant-
negative mpl isoforms causes thrombocytosis. The mouse phenotype
resembles in many ways human essential thrombocythemia (ET). For
instance, the increased platelet levels in the thrombocythemic mice are
accompanied by decreased mpl protein expression on platelets and normal
TPO levels. The combination of a thrombocytosis accompanied with normal
TPO levels in circulation and reduced c-mpl expression on platelets has been
observed in ET 153 and less frequently in sporadic cases of polycythemia vera
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and chronic idiopathic myelofibrosis 1. We have therefore an animal model at
hand that allows us to study the basis of the decreased c-mpl expression on
platelets and which may also allow the testing of future ET therapies.
Fig. 1 Alignment of the C-terminus of mpl-tr with a short peptide sequence, 10
amino acids in length, contained in the extracellular domain of the protein
Kremen. The unique sequenc at the C-terminus of mpl-tr is due to a shift of the
reading frame at the alternate splice junction of exon 8/11. The mouse mpl-tr petide is
terminated after 30 and the human form after 21 amino acids. The sequence in
Kremen homologous to mpl-tr is conserved amongst the species rat, mouse (m) and
human (h). A consensus sequence is depicted.
Receptor isoform-mediated proteolysis as a novel regulatory
mechanism
Mechanistically, dominant-negative receptor variants can form non-functional
heterodimers with the full-length receptor or, when expressed as secreted
‘soluble’ isoforms, compete with the receptor for ligand binding 63. In this work
I have discovered a third mechanism, in which the mpl isoform mpl-tr
mediates protein degradation of the full-length receptor by a cathepsin-like
cysteine protease activity, suggesting the lysozome as the degradative
compartment. Future studies, using an array of different protease inhibitors
and lysomotropic agents as well as inhibitors of protein trafficking and studies
on the subcellular localization of mpl in dependence on mpl-tr expression
should clarify the precise mode of mpl destruction.
I have also been able to demonstrate that the unique sequence at the C-
terminus of mpl-tr is essential for its function. Interestingly, the wild type form
of mpl-tr fails to be secreted 74. In contrast, truncated mpl forms consisting of
the extracellular domain only, therefore lacking the unique C-terminus of mpl-
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tr, are readily secreted into the cell culture supernatant 74,75. In one possible
scenario, the C-terminus of mpl-tr prevents the secretion of mpl-tr and directs
the putative mpl/mpl-tr dimer to traffic instead along the endosomal-lysosomal
route. Increasing acidification of the endosomal vesicle would cause the dimer
to disassemble allowing mpl-tr to be recycled. This model would explain why
mpl-tr expression is apparently not affected by mpl protein. Preliminary
fluorescent microscopy studies show that mpl-tr is located to the ER, the site
of mpl-tr synthesis, but also to other unidentified vesicular structures.
Interestingly, the C-terminal mpl-tr peptide motif appears to be present in the
Kremen (Krm) protein (Fig. 1). Kremen functions in a sophisticated
mechanism of Wnt signal inhibition, whereby an activating coreceptor, LDL-
receptor-related protein 6 (LRP6), is segregated and removed by
internalization229. LRP6 clearance was observed as a consequence of ternary
complex formation in Krm- and LRP6-transfected cells provided with Dickkopf
(Dkk) protein. After application of Dkk1, the membrane localization of tagged
versions of LRP6 and Dkk1 diminished quickly. The proteins were instead
subsequently enriched in intracellular vesicles, with a slight reduction in LRP6
levels. This decrease was interpreted as degradation and it will be important
to verify this hypothesis with further studies. It will be especially interesting to
determine whether Krm is being recycled or whether it is also being degraded.
A functional role of the Kremen peptide sequence, which aligns with the mpl-tr
C-terminus, would suggest that Kremen, in analogy to mpl-tr, is recycled.
Further structure function analysis of the C-terminal sequence of mpl-tr will
hopefully allow us to define a minimal functional peptide motif. It will be of
interest to determine if such a peptide motif is also present in other receptor
isoforms or proteins other than Kremen that mediate proteolysis.
Characterization of a novel mpl- and GATA-regulated gene
In the second part of my thesis work, I have characterized a novel gene,
which has been named GASIP for GATA-1 regulated SIAH Interacting
Protein. GASIP is downregulated in hematopietic cell lines when mpl is
expressed. So far it is not clear, which signaling events initiated by mpl lead to
GASIP repression. Moreover, downregulation of GASIP in mpl-expressing cell
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lines can occur in both a TPO-dependent and –independent fashion and
studies on primary megakarycocytes should clarify the role of mpl signaling in
regulating GASIP. The expression of GASIP appears to be to some extent
under the transcriptional control of GATA-1 in vivo. In contrast to mpl, GATA-1
is a negative regulator of megakaryocyte cell proliferation 185,188. However,
target genes of GATA-1, which mediate the anti-proliferative effect, have
remained elusive. The finding that mpl and GATA have opposite effects on
both proliferation and on GASIP expression, make GASIP a candidate GATA-
1 target gene involved in growth inhibition. In one possible model, GATA-1
constitutively activates GASIP transcription in the megakaryocytic precursors
and together with other factors GASIP would exert an anti-proliferative effect
and/or play a role in differentiation. Contrarily, activation of TPO-R triggers the
repression of anti-proliferative genes and GASIP could be such a target gene
for repression. The potential function of GASIP in the megakaryocytic lineage
will be tested by generating mice which express GASIP as a transgene under
the control of the mpl promoter. To assure overexpression of GASIP, the 3’
UTR of GASIP, which is AU-rich and probably exerts a negative effect on
mRNA stability, has been removed in the transgenic construct (Fig. 2A).
The highest expression of GASIP was found in granulocytes. Interestingly, the
assembly of transcription factor binding sites in the GASIP promoter resemble
the composition of the arch-typical eosinophilic promoter of the eos47 gene.
The promoter of the eos 47 gene (encoding EOS47, the avian ortholog of the
mammalian melanotransferrin gene) consists of binding sites for Myb-, Ets-,
C/EBP-, and GATA-type transcription factors 224,225, all elements also
contained in the GASIP promoter (Fig.3). Further, the double GATA site in the
GASIP promoter appears to be specific for eosinophil expression 207. An
available embryonic stem cell clone containing a gene-trap insertion in intron
2 of GASIP (Fig. 2B) will allow the generation of a mouse with a GASIP gene
disruption. Such a mouse would be a valuable tool in studying a putative
function of GASIP in eosinophilic granulocytes.
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Fig. 2.  Tools for the in vivo analysis of GASIP function. (A) The construct used for
the over-expression of GASIP in the megakaryocytic lineage. A 2kb mpl promoter
fragment has been cloned in front of mGASIP cDNA followed by a SV40-derived
polyA signal (not shown). The AU-rich 3’UTR of GASIP, which probaly functions as
a negative regulator of mRNA stability, has been removed. Several transgenic
founders are available. (B) A gene-trap vector insertion in intron 2 of mGASIP has
been identified in 3 independent mouse ES clones. These cells will allow the study of
GASIP gene disruption in a mouse model. The presence of the lacZ gene in the vector
insertion will be useful for GASIP expression studies.
To gain insights into the potential function of GASIP protein, I performed
Yeast-Two-Hybrid screens. Notably, the tumor suppressor SIAH was
identified as a binding partner of GASIP protein and one could speculate
whether GASIP could contribute to the anti-proliferative effect of SIAH.
Additionally, cytoskeletal proteins and the RNA binding protein hnRNP E1
were found to be GASIP interacting proteins. The binding of GASIP to filamin,
actinin and a kinesin suggests a potential function of GASIP in cytoskeletal
Fig. 3. Alignment of the
GASIP and EOS47 promoter.
The promoter  of  the
eosinophilic EOS47 gene
contains several transcription
factor elements, which are also
found in the GASIP promoter.
Of particular importance in
e o s i n o p h i l i c  l i n e a g e
commitment are members of the
C/EBP family of transcription
factors and GATA-1.
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rearrangements with potential importance in the differentiation of both
megakaryocytes and granulocytes.
Of particular interest is the interaction of GASIP with the heterogeneous
nuclear ribonucleoprotein E1 (hnRNP E1). The hnRNPs E1 and E2 proteins
share over 80% homology, which makes it likely that GASIP also interacts
with hnRNP E2. Both, hnRNPs E1 and E2, function as regulators of
cytoplasmic mRNAs of key factors in erythroid and granulocytic differentiation.
In erythroid-precursor cells, hnRNP E1 regulates translation of reticulocyte 15-
lipoxygenase (LOX) mRNA specifically, through the differentiation-control
element (DICE) in the 3' UTR of the LOX 226,227. LOX is a key enzyme in
erythroid-cell differentiation. It catalyses the dioxygenation of intact
phospholipids in mitochondrial membranes and participates in their
breakdown in the final steps of erythrocyte maturation.
By a similar mechanism, hnRNP E2 inhibits the translation of C/EBPalpha, the
principal regulator of granulocytic differentiation. Importantly, the BCR-ABL
oncoprotein induces expression of hnRNP E2, which blocks the production of
C/EBP and causes an arrest in granulocytic differentiation 228. Because
GASIP interacts with hnRNP through its N-terminus and with the E3-ubiquitin
ligase SIAH through its C-terminus, it is feasible that GASIP, hnRNP E1/2 and
SIAH can form a complex. In a highly speculative model, GASIP would recruit
hnRNP E1/2 for ubiquitin-mediated proteolysis and thus promote
differentiation and inhibit proliferation
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